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ABSTRACT
ESTABLISHMENT AND REGULATION OF EPITHELIAL ENHANCERS BY P63
Enrique Lin Shiao
Shelley L. Berger

The transcription factor p63 is a key mediator of epidermal commitment, development, and
differentiation. Point mutations in p63 in human patients lead to developmental defects, including
orofacial clefting, one of the most common congenital defects in humans. To date, knowledge is
limited about how pivotal is p63’s role in human craniofacial development, due in part to a lack of
tractable models to study de novo expression of p63 and its role at developmentally regulated
genes. Using an inducible trans-differentiation model, combined with epigenomic sequencing and
multi-cohort meta-analysis of GWAS data, we show that p63 establishes enhancers at
craniofacial development genes to modulate their transcription. We further identify histone
methyltransferase KMT2D as a key interacting partner of p63 at these enhancers and identify a
novel role for this histone methyltransferase in maintaining epithelial homeostasis. Our results
demonstrate that disease-specific substitution mutation in the DNA binding domain or SAM
protein interaction domain of p63 respectively eliminate or reduce establishment of these
enhancers.

Finally, we show enhancers established by p63 are highly enriched for SNPs

associated with nonsyndromic cleft lip +/- cleft palate (CL/P). These orthogonal approaches
indicate a strong molecular link between p63 enhancer function and CL/P, illuminating molecular
mechanisms underlying this developmental defect and revealing vital regulatory elements and
new candidate causative genes.
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CHAPTER 1: Introduction

1.1: Epigenetics
One of the most fascinating hallmarks in biology is how multicellular organisms can form
from a single cell and how cells with an identical genome can show so many different
phenotypes. The main difference between distinct cells in an organism comes down to what
genes are expressed in each cell and this is in part modulated by the organization of DNA into
chromatin. In chromatin, DNA wraps around proteins known as histones that function as spools to
allow DNA to be organized in a particular way within the nucleus. Both DNA and histones can be
covalently modified to modulate the organization of DNA in the nucleus and ultimately regulate
gene expression (Figure 1.1). The study of heritable changes in gene expression patterns that do
not involve modifications in the DNA sequence is known as epigenetics1,2. Epi- comes from the
Greek and means over, outer or above.

Figure 1.1: Chromatin can be covalently modified to modulate its organization in the
nucleus. Figure adapted from Weaver et al.3

1

Many epigenetic mechanisms have been identified thus far, including the role of DNA
methylation, histone modifications and long non-coding RNAs in modulating gene expression

1–4

.

However, how all these different mechanisms act in concert to regulate complex processes, such
as lineage specification and development, remains to be elucidated. Additionally, how disruption
of these mechanisms can lead to disease is largely unclear. The completion of the human
genome project and the advancement of next generation sequencing technologies have opened
up a plethora of new avenues to study epigenetics and start to answer some of these questions.

1.2: From enhancers to lineage specification
In 1972 the geneticist Susumu Ohno coined the term “junk DNA” to refer to parts of the
5

genome that did not encode for proteins and which many people believed had no function . The
completion of the human genome project in 2003 showed that only about 1% of the human
6,7

genome are protein-coding regions, encompassing about 21.000 protein-coding genes .
However, a great amount of evidence has accumulated since then to demonstrate that many
parts of the non-coding genome perform important regulatory functions to modulate gene
expression

4,8–10

.

Cis-regulatory elements, in particular, are regions of non-coding DNA that regulate
8

transcription of neighboring genes . The best characterized cis-regulatory elements include
promoters and enhancers, both of which can be bound by transcription factors to modulate
downstream gene expression. Promoters are primarily localized ~50 base pairs(bp) upstream or
downstream of the transcription start site (TSS), while enhancers can be localized upstream,
downstream, within intronic regions or even mega bases apart from the genes they regulate

11,12

.

While promoters are sufficient to assemble RNA Pol II machinery to start transcription,
transcription is often low in the absence of enhancers

2

11,13

.

The first enhancer was identified about 40 years ago, as part of the sequence of the
SV40 virus genome

14,15

. Isolation and introduction into a reporter in HeLa cells demonstrated over
14

100-fold enhancement of transcription of a reporter gene . Since then, many enhancers have
been identified in mammalian genomes and their biochemical and functional properties have
been thoroughly investigated

10,12,13

. Comparative genomics facilitated the identification of

enhancers by looking at highly conserved non-coding regions across vertebrates and
mammals

16–18

. With the advent of next-generation sequencing, many more enhancers have been

described in the past decade and key features have been found to de novo identify enhancers:
open chromatin, decorated by histone modifications (H3K27ac, H3K4me1, H3K122ac and
H4K16ac), bound by RNA Pol II and transcription factors; and expression of enhancer RNAs
(eRNAs)

19–26

.

(Figure

1.2)

Figure 1.2: Anatomy of enhancers. Specific chromatin features have been found to be
characteristic to enhancers, including activating histone modification marks, depletion of
nucleosomes, active transcription and binding of transcription factors.

3

Enhancers and promoters are associated to cell fate determination, as they can be bound
by lineage specific transcription factors and remodeled to regulate tissue specific transcription.
The current model for how enhancers work posits that active enhancers bound by transcription
factors can loop towards the promoter through protein-protein interactions at both sites to activate
downstream transcription of specific genes

27–31

(Figure 1.3). Many questions remain around

enhancers, particularly how enhancers are established, maintained and inherited through cell
12

divisions is not fully understood .

Figure 1.3: Enhancers are non-coding regions of DNA that regulate cell-type specific gene
expression and maintain cell identity. Local expression of a gene during brain and limb
development is achieved by binding of tissue specific transcription factors to distinct upstream
enhancers and looping of the enhancer to the promoter region. Figure adapted from Visel et al.

4

27

Hematopoiesis is perhaps one of the best studied models for lineage commitment and
the β-globin locus involved in erythroid differentiation is among the first and most thoroughly
characterized gene clusters at which long-range interactions between a distal enhancer and
target β-globin promoters have been observed

29,32,33

.During hematopoiesis, hematopoietic stem

cells (HSC) undergo transcriptional and epigenetic changes associated with lineage restriction
and cell specification to give rise to all the hematopoietic cell types

34–36

. Key transcription factors,

such as GATA1 and GATA2 have been identified in this process that modify chromatin structure
and gene expression to regulate cell fate decisions. Translocations in the the β-globin locus have
been shown to result in thalassaemias even when substitution mutations have not been found in
the the β-globin genes, showing that diseases can emerge as a consequence of disruption of
37

enhancer function .
Genetic variation in distant enhancers has been linked to many more human Mendelian
disorders, including pre-axial polydactyly due to mutations in an enhancer controlling sonic
38

hedgehog (SHH) , Holt-Oram syndrome (exhibiting cardiac and limb malformations) due to
mutations in an enhancer controlling TBX5

39

and many other disorders

40–42

. Importantly genome-

wide association studies (GWAS) have shown that the majority of disease-associated variants
are not localized within protein-coding regions but instead are localized at non-coding regions and
many could possibly be localized at enhancers

43,44

.

In order to understand how enhancers may influence different diseases, it is necessary to
expand our knowledge about how enhancers are specified in different lineages and fates beyond
the hematopoietic pathway and how mutations in enhancer regions can lead to dysregulation of
gene expression in different cell types.

1.3: The epidermis

5

The surface epithelium of the skin or epidermis forms the outermost layer of cells in the
body, providing a direct physical, chemical and immunological barrier between the body and the
environment. The epidermis is self-renewing, with progenitor basal keratinocytes giving rise to all
45

the differentiated layers of the stratified epidermis (Figure 1.4). This differentiation process
occurs through an outward migration and terminal differentiation program that is tightly controlled
by epigenetic changes and by spatiotemporal expression of epithelial specific genes.

Figure 1.4: The epidermis is composed of stratified layers that stem from the progenitor
basal keratinocytes. Schematic of an epidermis section showing the different layers. Figure
46

taken from Anatomy of the Human Body .

Dysfunction of epidermal lineage specification and differentiation is associated with over
47

a hundred human genetic diseases, impacting over 20% of the population . Some of the most
severe diseases include epidermolysis bullosa (manifested by skin blistering and erosions),
squamous cell carcinomas, as well as ectodermal defects (showing orofacial clefting and limb
47

malformations) . Given the high incidence of epidermal disorders in humans it is imperative to

6

understand the molecular mechanisms that lead to epithelial specification and differentiation and
study how these processes are affected in disease.
The mammalian epidermis derives from the ectoderm through a process of lineage and
48

cell fate specification that results in the stratified squamous epithelium . The consequent
differentiation of basal epidermal cells into terminally differentiated cells of the cornified layer has
been thoroughly studied and characterized

45,49

. However, the early events that lead to the

commitment of epidermal stem cells and progenitor cell populations are still not completely
understood.
Bone morphogenetic protein (BMP) and retinoic acid (RA)

50–52

initially specify the

epidermal lineage from the lateral surface ectoderm. The surface ectoderm is a single-layered
epithelium characterized by the expression of markers keratin 8(KRT8) and keratin 18(KRT18).
In the presence of epidermal growth factor, fibroblast growth factor and insulin, the surface
ectoderm commits to form the stratified epidermal progenitors known as basal membrane
keratinocytes which express keratin 5(KRT5) and keratin 14(KRT14)

52,53

. The basal keratinocytes

can then further differentiate to produce stratified multi-layered skin.
Mouse developmental models, human syndromes and in vitro epidermal differentiation of
pluripotent stem cells (PSCs) have begun to uncover key transcription factors required for
epidermal lineage specification and differentiation. A key transcription factor involved in regulating
gene expression programs to modulate these processes is p63, which has been termed a master
regulator of epidermal development

54,55

.

1.4: Transcription factor p63
Transcription factor p63, a member of the p53 family of proteins, is almost exclusively
55

expressed in epithelial cells . Unlike p53, numerous N- and C-terminal variants of p63 can be

7

transcribed to yield polypeptides that exhibit different functions in transcriptional control, with
ΔNp63α as the most abundant and best characterized isoform in epithelial cells (Figure 1.5)

55,56

.

Importantly, the high sequence identity between the DNA binding domains (DBD) of p53 and p63
allow them to bind to the same DNA consensus motif.

Figure 1.5: p63 can be transcribed as 6 isoforms. Including ∆N and TA (transcriptional
activation domain) isoforms. Disease related mutations in the DBD and SAM domain of p63
are highlighted, as well as the high sequence identity with p53.

57

While deletion of Trp53 (encoding the p53 protein) shows no phenotype at birth ,
deletion of Trp63 (encoding the p63 protein) in mice leads to clear developmental and
morphological defects in the squamous epithelia and epidermis, leading to abnormal craniofacial
development, truncated limbs and loss of salivary glands, hair follicles and teeth

54,55

(Figure 1.6).

In humans, germline missense mutations in p63 cause ectodermal dysplastic syndromes, leading
to cleft lip/palate and limb malformations

47,58,59

8

. Interestingly, these mutations are largely

clustered in either the DBD or the sterile alpha motif (SAM) domain and show clear differences in
60

the location and severity of phenotypes . These genetic data strongly implicate p63 in critical
epithelial cell processes, including establishment of epithelial identity.
Although p63 mutations have not directly been linked to tumorigenesis

61,62

, loss of p63

has been observed in the epithelial to mesenchymal transition (EMT) in several types of cancers,
including human breast and human prostate adenocarcinoma

63,64

. Our laboratory previously

demonstrated that p53 family member proteins, including p63, can directly bind to nucleosome65

occluded DNA sequences, displaying properties more commonly observed in pioneer factors .
Pioneer factors are transcription factors that can bind to condensed chromatin and recruit
chromatin modifiers and other transcription factors to regulate the chromatin landscape and
enhancer activity

66–69

. They are critical for specifying cell lineages, presumably through their
67

ability to regulate cell type-specific enhancer networks . While the importance of p63 in the
development and differentiation of epithelial tissues has been demonstrated in mouse knockout
models and human syndromes, the biochemical role of p63 in de novo epithelial lineage
commitment and the molecular and epigenetic mechanisms by which it maintains epithelial cell
identity though enhancer regulation and pioneer factor activity remain to be elucidated. A main
reason for this is the difficulty of studying these processes during embryonic development and a
70

lack of tractable models to do this .

1.4: p63 remodels chromatin during epidermal development
While the importance of p63 in regulating epidermal development has been known for
almost 30 years now

54,55

, the molecular mechanisms by which it achieves this have only recently

begun to be elucidated. Early on, it was recognized that p63 could bind upstream of genes to
either activate or repress their transcription

55,71

. This mechanism was shown to be crucial for

proliferation and differentiation of human epidermal keratinocytes

9

72–74

, regulation of signaling

pathways involved in ectodermal organogenesis
potential of epidermal progenitor stem cells

76

75

as well as maintenance of proliferative

and more recently regulation of nuclear shape and
77

expression of nuclear envelope-associated genes .
A more complete picture of how p63 engages with chromatin to regulate epidermal
development emerged with the advent of genome-wide high throughput sequencing techniques to
profile changes in chromatin, including chromatin-immunoprecipitation sequencing (ChIP-Seq)

78

to profile changes in histone modification profiles and binding profiles of transcription factors, as
well as assay for transposase-accessible chromatin sequencing (ATAC-Seq)

79

to profile open and

closed chromatin regions. Initial experiments demonstrated that p63 binds to over 7000 sites in
the genome in human foreskin keratinocytes, primarily in intronic regions and upstream of
80

promoters . Furthermore, results demonstrated that p63 bound sites were enriched for H3K4
80

monomethylation, a histone modification characteristic of enhancers . Integrative analysis
suggested that genes closest to p63 bound sites were downregulated when p63 was knocked
81

down , correlating genome-wide binding of p63 to transcriptional changes and identifying a
plethora of new genes regulated by p63.
Other transcription factors and chromatin modifying proteins involved in co-regulation of
epidermal development with p63 were also identified through genome-wide and biochemical
82

experiments, including chromatin reorganizer SATB1 , chromatin remodeler BRG1

83

and

80

transcription factor TFAP2C . Further experiments showed correlation between p63 binding and
acetylation of histone tail H3 lysine 27 (H3K27ac) during keratinocyte proliferation and
84

differentiation suggesting a key role for p63 in regulating epidermal specific enhancers . A further
study demonstrated cooperation between the BAF chromatin remodeling complex and p63 and
showed that both are required in an invitro human epidermal differentiation assay to maintain
85

open chromatin regions characteristic of keratinocytes .
More recently, experiments using an in vitro epidermal differentiation assay from PSCs
52

suggested TFAP2C, but not p63, is sufficient to initiate surface ectoderm differentiation . These

10

data did show, however, that p63 is necessary for maturation of this differentiation program to
specify the epidermal lineage. Data from the same group showed p63 could specify different
51

transcriptional programs depending on which morphogens it is exposed to . Another recent
single-cell study showed p63 is able to remodel open chromatin regions to specify the epidermal
lineage independently of previously described co-regulatory transcription factors

86

and

unpublished work from the Zhou lab suggests a novel interaction between p63 and CTCF to
87

modulate chromatin architecture in skin keratinocytes . Together the data thus far points towards
a key role for p63 in regulating epidermal lineage specification, however, many questions remain
around the mechanism and how p63 engages other transcription factors during this process.
An additional fundamental question is whether dysregulation of p63’s interaction with
chromatin plays a role in disease. As mentioned above, substitution mutations in p63 lead to
ectodermal dysplastic syndromes, including orofacial clefting and limb malformation
Furthermore, p63 is amplified in a subset of squamous cell carcinomas

89–91

54,58,88

.

. Nevertheless, the

molecular mechanisms behind these disorders are only recently being elucidated. A study
published last year demonstrated that enhancer reprogramming via p63 in the squamous subtype
92

of pancreatic ductal adenocarcinoma promoted migration, invasion and tumor growth . Another
study showed that keratinocytes from patients with electrodactyl, ectodermal dysplasia, and cleft
lip/palate syndrome (EEC), exhibit a clear downregulation of epidermal genes and loss of
93

epidermal enhancers . Finally, murine studies and human genome wide association studies
(GWAS) have suggested a connection between p63 and clefting of the lip and the palate

80,94–96

;a

molecular link however remains to be demonstrated.

1.5: Cleft lip/palate
Mutations in p63 in humans are rare, however, orofacial clefting [with its distinct subtypes
cleft lip +/- cleft palate (CL/P) and cleft palate only (CPO)] is a key feature of mutant p63

11

syndromes, and is one of the most common congenital defects world-wide with an approximate
97

prevalence of 1:700 births . The etiology of orofacial clefting is complex, with involvement of
genetic and environmental factors. To date, over 400 different human syndromes have been
reported showing orofacial clefting as part of their phenotypic spectrum. However, more than 70%
of CL/P cases and more than 50% of CPO cases are non-syndromic (ns), presenting as isolated
phenotypes with absence of other organs and systems affected, and hence their etiology remains
largely unclear

97–100

. The commonality and complexity of the constellation of orofacial clefting

syndromes suggests involvement of p63-linked regulatory dysfunction.
Murine models have been crucial in understanding lip and palate development.
Nonetheless, mutations and knockout of proteins involved in human CL/P in mice rarely show
clefting of the lip, with clefting primarily observed in the secondary palate

101,102

. Genome-wide

association studies (GWAS) and other genetic approaches in human nsCL/P patients have
identified 40 risk loci that show robust associations of single nucleotide polymorphisms (SNPs)
with nsCL/P

100,103–105

. A provocative finding is that the majority of SNPs associated to nsCL/P are

not found within protein-coding exons but rather at intronic and intergenic regions, and, for the
vast majority of these SNPs, the molecular mechanism underlying nsCL/P pathogenesis remains
unknown. A single case in a family with CL/P has been reported in which a substitution mutation
95

in p63 disrupts its binding to an enhancer and affects transcription of IRF6 . Whether CL/P
associated SNPs function in a similar way is unknown, and most broadly, how general is
enhancer disruption in developmental diseases, remains to be elucidated.

In the following chapters I will discuss two studies in which we investigated the role of
p63 in human craniofacial development (Figure 1.6), and in the pathogenesis of orofacial clefting.
In the first study,

we developed an inducible trans-differentiation model that reveals p63

interaction with chromatin when expressed de novo and p63 regulation of gene expression. Our
strategy encompassed a combination of epigenomic assays, including ATAC-seq, ChIP-seq of

12

p63 and the active enhancer histone modification H3K27ac, along with analysis of nsCL/P GWAS
data. In parallel, for our second study, we combined mass spectrometry and genome-wide
approaches to identify novel interactors of p63 at enhancers and characterized their function. Our
results reveal p63 establishment of enhancers, displaying increased chromatin accessibility and
de novo H3K27 acetylation, at critical craniofacial genes and demonstrate that substitution
mutations in p63 abrogate this function. We identify KMT2D as a novel partner of p63 at epithelial
enhancers and determine a novel role of this histone methyltransferase in coordinating epithelial
homeostasis and differentiation. Further, we validate known genes and identify novel candidate
genes and the enhancers that regulate them via p63, that might play a role in nsCL/P
pathogenesis. Lastly, we show enhancers established by p63 are highly enriched for SNPs
associated with nsCL/P, providing novel mechanistic insights into regulation of pathogenesis by
CL/P-associated SNPs.

Figure 1.6: Central Hypotheses. While the importance of p63 in regulating epidermal
development has been thoroughly studied, the molecular mechanisms by which it achieves this
are not completely understood. Through investigation of p63’s first encounter with chromatin I aim

13

to understand its role in epithelial enhancer establishment and how this process might be affected
in cleft lip/palate pathogenesis.
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CHAPTER 2: p63 establishes epithelial enhancers at critical craniofacial development
genes

2.1: Introduction
The transcription factor p63, a member of the p53 family of proteins, is a key mediator of
1

epithelial cell processes, including establishment and maintenance of epithelial identity . Deletion
of Trp63 (encoding the p63 protein) in mice leads to developmental and morphological defects in
the squamous epithelia and epidermis, leading to abnormal craniofacial development, truncated
2,3

limbs, and loss of salivary glands, hair follicles and teeth . In humans, germline missense
mutations in p63 cause ectodermal dysplastic syndromes, which are characterized by orofacial
clefting and limb malformations

4–6

. Interestingly, these mutations are largely clustered in either

the DNA Binding Domain (DBD) or the protein-protein interaction Sterile Alpha Motif (SAM)
domain; amino acid substitutions show clear differences in the physical location and severity of
7

phenotypes . p63 can bind directly to chromatin to change the chromatin landscape during
keratinocyte differentiation

8–10

. However, the role of p63 in de novo epithelial lineage commitment

and how p63 amino acid mutations lead to defects in this process, remain unknown.
Mutations in p63 in humans are rare, however, orofacial clefting [with its distinct subtypes
cleft lip +/- cleft palate (CL/P) and cleft palate only (CPO)] is a key feature of mutant p63
syndromes, and is one of the most common congenital defects world-wide with an approximate
11

prevalence of 1:700 births . The etiology of orofacial clefting is complex, with involvement of
genetic and environmental factors. To date, over 400 different human syndromes have been
reported showing orofacial clefting as part of their phenotypic spectrum. However, more than 70%
of CL/P cases and more than 50% of CPO cases are non-syndromic (ns), presenting as isolated
phenotypes with absence of other organs and systems affected, and hence their etiology remains
largely unclear

11–14

. The commonality and complexity of the constellation of orofacial clefting

syndromes suggests involvement of p63-linked regulatory dysfunction.
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Murine models have been crucial in understanding lip and palate development.
Nonetheless, mutations and knockout of proteins involved in human CL/P in mice rarely show
clefting of the lip, with clefting primarily observed in the secondary palate

15,16

. Genome-wide

association studies (GWAS) and other genetic approaches in human nsCL/P patients have
identified 40 risk loci that show robust associations of single nucleotide polymorphisms (SNPs)
with nsCL/P

14,17–20

. A provocative finding is that the majority of SNPs associated to nsCL/P are

not found within protein-coding exons but rather at intronic and intergenic regions, and, for the
vast majority of these SNPs, the molecular mechanism underlying nsCL/P pathogenesis remains
unknown. A single case in a family with CL/P has been reported in which a substitution mutation
in p63 disrupts its binding to an enhancer and affects transcription of IRF6

21

. Whether CL/P

associated SNPs function in a similar way is unknown, and most broadly, how general is
enhancer disruption in developmental diseases, remains to be elucidated.
In this study we investigated the role of p63 in human craniofacial development, and in
the pathogenesis of orofacial clefting. We used an inducible trans-differentiation model that
reveals p63 interaction with chromatin when expressed de novo and p63 regulation of gene
expression. Our strategy encompassed a combination of epigenomic assays, including ATACseq, ChIP-seq of p63 and the active enhancer histone modification H3K27ac, along with analysis
of nsCL/P GWAS data. Our results reveal p63 establishment of enhancers, displaying increased
chromatin accessibility and de novo H3K27 acetylation, at critical craniofacial genes and
demonstrate that substitution mutations in p63 abrogate this function. We validate known genes
and identify novel candidate genes and the enhancers that regulate them via p63, that might play
a role in nsCL/P pathogenesis. Lastly, we show enhancers established by p63 are highly
enriched for SNPs associated with nsCL/P, providing novel mechanistic insights into regulation of
pathogenesis by CL/P-associated SNPs.
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2.2: Results
2.2.1: p63 remodels chromatin to establish enhancers, upregulating epithelial and
inflammation genes
To determine whether p63 has the ability to remodel the chromatin landscape to establish
epithelial enhancers, we set up a doxycycline-inducible system to express the ∆NP63α isoform
(hereafter referred to as p63) in human BJ dermal fibroblasts (ATCC CRL-2522). After 48 hours,
p63 reaches an expression level comparable to endogenous levels observed in undifferentiated
normal human epidermal keratinocytes, and expression levels are maintained without increase at
72 hours (Supplemental Figure 2.1 a). This p63 isoform was selected because it is the most
abundant isoform in epithelial cells, is not expressed in fibroblasts, and has been demonstrated to
play a fundamental role as a regulator of epithelial fate and keratinocyte differentiation

22–24

.

Expression of p63 was induced for 72 hours, followed by p63 chromatin precipitation
(ChIP-seq to assess p63 binding genome-wide), ATAC-seq (to assess open chromatin), and
H3K27 acetylation (H3K27ac) ChIP-seq (Fig 2.1a). We observed an increase in ATAC-seq
chromatin accessibility and H3K27 acetylation (H3K27ac) at p63-bound sites in fibroblasts
expressing p63 compared to control fibroblasts with empty vector (Fig 2.1b, Supplemental Fig.
2.1b). 40K sites were bound by p63, of which 40% were previously closed chromatin sites
becoming open only after ectopic expression of p63 (Fig 2.1c, Supplemental Fig. 2.1b;
17156/27441 peaks), while a smaller proportion were unchanged or closed after p63 expression
(14991 open before and after; 10302 closed). Further, 40% of these p63 bound sites were
flanked by H3K27ac with approximately 60% of these sites showing de novo H3K27ac (Fig 2.1d,
Supplemental Fig. 2.1b; 12071/20190). Partitioning of p63 bound sites by distance to transcription
start sites (TSS) revealed that the majority of p63 sites are located at intergenic and intronic
regions at a median distance of 27kb (Figs 2.1e,f), a distribution that is characteristic of
enhancers. Overlaying published micrococcal nuclease (MNase) datasets in human fibroblasts

25

with our p63 ChIP sites revealed that 55% of sites bound by p63 when ectopically expressed are

23

nucleosome-occupied in fibroblasts, and 75% of these become open and devoid of nucleosomes
upon ectopic expression of p63 (Supplemental Fig. 2.1c), expanding on previous work that
showed p63 has the ability to bind to closed chromatin and remodel the enhancer landscape
8

during keratinocyte differentiation . Overall, these data reveal that de novo binding of p63 to
chromatin leads to global changes in the enhancer landscape, specifically, to the establishment of
enhancers characterized by de novo chromatin accessibility and by H3K27ac flanking p63-bound
sites.

Figure 2.1. p63 remodels chromatin to establish enhancers A) Experimental setup showing
inducible expression of p63 and downstream epigenomic analyses. B) Heatmap of p63 ChIPseq,
ATACseq and H3K27ac ChIPseq (+/- 2.5kb from peak center) in control fibroblasts expressing an
empty vector(ctrl) and in fibroblasts expressing p63 for 72 hours. C) Graph of called p63 peaks
partitioned into open and closed chromatin according to ATACseq results in fibroblasts ctrl and
fibroblasts + p63. D) Pie chart depicting differences in chromatin landscape at p63 called peaks in
ctrl and after ectopic expression of p63 showing clear increase in chromatin accessibility (blue:
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open) and H3K27ac (patterned lines). E) Distance to nearest TSS for all p63 peaks. F)
Partitioning of p63 peaks into different genomic features.

We examined the transcriptional consequence of these changes in the chromatin
landscape, via RNA-seq after ectopic expression of p63 for 72 hours in fibroblasts. 1960 genes
were upregulated upon ectopic expression of p63 (Fig 2.2a; fold change > 1.5 and FDR < 0.05),
validating known p63 targets (IRF6, LCE1C, IVL, ITGB4 and SHH)

26,27

and identifying over 1000

genes previously not known to be regulated by p63 (full list in Supplementary Table 2.1). Gene
ontology (GO) analysis of all upregulated genes showed enrichment of cell-cell adhesion
categories characteristic of epithelial cells and important for epithelial lineage specification (Fig
2.2a). Other categories were interferon, inflammation, and immune pathways (Fig 2.2a),
consistent with previous reports showing p63 modulates epidermal development and
inflammation programs, and plays a crucial role in T-cell development through establishment of
the thymic epithelium

28–31

. Additionally, 1479 genes were downregulated upon expression of p63

(Supplemental Fig 2.1d, fold change > 1.5 and FDR < 0.05), consistent with previous reports of
p63 playing a repressive role at specific genes (COL6A2, CITED2, CDH13)

27,28

and uncovering

over 1000 new genes downregulated by p63.
We compared changes in the chromatin landscape to transcription, finding chromatin
accessibility and H3K27ac increased at enhancers and promoters of genes that became
upregulated upon expression of p63 in fibroblasts (Fig 2.2b,c).

The largest fold change in

chromatin accessibility was found at genes that became upregulated (Fig 2.2b, Supplemental Fig
2.1e). H3K27ac decreased at genes downregulated and increased dramatically at genes that
were upregulated (Fig 2.2c, Supplemental Fig 2.1f). To validate these findings, we examined the
previously known p63-regulated gene IRF6

21,32,33

: the p63-dependent IRF6 enhancer showed de

novo chromatin accessibility and H3K27ac, and establishment of this enhancer was accompanied
by de novo activation of IRF6 expression in fibroblasts (Fig 2.1d). We also observed enhancer
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establishment and transcriptional activation of genes encoding the F11 receptor (F11R) and
integrin subunit alpha 7 (ITGA7) (Fig 2.2e, Supplemental Fig 2.1g). Thus, our data provide the
first evidence that p63 can establish enhancers, revealing known and new gene targets of p63
linked to epithelial cells and inflammation, and uncovering enhancers that might regulate their
expression.

Figure 2.2: p63 upregulates epithelial and inflammation genes downstream of enhancer
establishment. A) Heatmap of z-scored RNAseq results for 1960 genes upregulated (fold
change > 1.5 and FDR < 0.05) upon ectopic expression of p63, and top gene ontology categories
showing enrichment of epithelial and inflammations categories among upregulated genes. B)C)
Boxplots showing increased chromatin accessibility and H3K27ac at p63/KLF4 sites +/- 250bp
near upregulated genes (* p-Value < 10E-10). D) UCSC genome browser tracks showing
transcriptional activation of IRF6 and de novo H3K27ac and ATACseq signal at an enhancer
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upstream of IRF6 in fibroblasts with ectopic expression of p63 (grey highlighted box). E) UCSC
genome browser tracks showing transcriptional activation of F11R and de novo H3K27ac and
ATACseq signal within introns of F11R in fibroblasts with ectopic expression of p63 (grey
highlighted boxes).

2.2.2: p63 and KLF4 co-establish keratinocyte specific enhancers to convert fibroblasts
into keratinocyte-like cells.
These results demonstrate that p63 can establish chromatin structures required for
expression of key epithelial specification genes. However, previous findings show conversion of
fibroblasts into keratinocyte-like epithelial cells requires co-expression of p63 and Kruppel-Like
Factor 4 (KLF4), and these keratinocyte-like epithelial cells share significant morphology,
34

functional characteristics, and gene expression patterns with basal epithelial keratinocytes . To
understand the molecular mechanisms and chromatin changes that underlie this crucial
conversion, we extended our system to temporal co-expression of p63 and KLF4 in fibroblasts
driven by the same doxycycline-induced promoter (see Fig 2.3a, Supplemental Fig 2.2a). Indeed,
keratin 14 (KRT14), a key biomarker of basal keratinocytes was upregulated only when p63 and
KLF4 were co-expressed, and was not upregulated with expression of either p63 or KLF4 (Fig
2.3a,2.3c, Supplemental Fig 2.2b). Our results thus confirm the requirement for both factors to
achieve conversion of fibroblasts into keratinocyte-like cells.
Broad GO analysis of the 2213 genes upregulated upon conversion showed high
enrichment of gene classes encompassing epidermal development, cell adhesion, and other
epithelial specific programs (Fig 2.3b, Supplementary Table 2.2). Many genes critical for
keratinocytes, including FOXN1, DSC2 and DSG1, were newly expressed (Fig 2.3c and
Supplementary Table 2.2), and others became upregulated over 1000-fold, including KRT14,
KRT6a, GJB4 and LAD1 (Fig 2.3c). As with ectopic expression of p63 alone, approximately 1000

27

genes were downregulated with ectopic expression of p63+KLF4 (Supplemental Fig 2.2c, fold
change > 1.5 and FDR < 0.05), including previously known repressed targets (CITED2, SATB2,
27

TGFB1I1, SHOX2) . Overall, the fold decreased enrichment and GO category specificity of
downregulated genes was much lower compared to the upregulated genes (Supplemental Fig
2.2c). Importantly, many key genes required for epidermal development and epithelial lineage
specification were only upregulated in the combined system, including JAG2, GRHL3 and SFN
(Supplemental Fig 2.2d, Supplementary Table 2), and, importantly, their dysregulation has been
implicated in developmental malformations including skeletal dysplasias and orofacial
clefting

29,35,36

. Additionally, the top 15 upregulated genes (via fold change p63+KLF4/ctrl) by the

combined system includes keratinocyte specific genes (e.g. KRT6a, KRT14) that are key
mediators of cell-cell adhesion programs (e.g. CDSN, LAD1, GJB4), as well as keratinocyte
differentiation (e.g. TGM5, FA2H), all of which were not upregulated when p63 was expressed
without KLF4 (Fig 2.3c).

Figure 2.3: Ectopic co-expression of p63 and KLF4 convert fibroblasts into keratinocytelike cells. A) Immunofluorescence of p63 and KRT14 in fibroblasts + p63 and fibroblasts

28

+p63+KLF4 showing KRT14 is only upregulated when both p63 and KLF4 are expressed. B)
Heatmap of z-scored RNAseq results for 2213 genes upregulated (fold change > 1.5 and FDR <
0.05) upon ectopic expression of p63+KLF4 showing high enrichment of epidermal and skin
related GO categories. C) Comparison of transcriptional regulation of the top 15 genes
upregulated in fibroblasts + p63+KLF4 showing both factors are required for upregulation of
keratinocyte specific genes.

To determine whether changes in transcription were a result of upstream enhancer
establishment by p63 and KLF4, we induced expression of both proteins for 72 hours, followed by
ATAC-seq and ChIP-seq of p63, KLF4 and H3K27ac. Our data revealed p63 bound to over 40K
sites in the genome and KLF4 to approximately 25K sites (Fig 2.4a, Supplemental Fig 2.2e,2.2f).
Because both proteins are needed for trans-differentiation, we hypothesized that co-bound sites
might play a crucial role in establishing key keratinocyte-specific enhancers. Our ChIP-seq
experiments revealed 13488 sites were co-bound by p63 and KLF4 (Fig 2.4a), primarily at
intronic, intergenic and promoter regions (Supplemental Fig 2.2g,2.2h). Sites co-bound by p63
and KLF4 showed a clear increase in chromatin accessibility at 80% of the sites, with 30% of the
sites became newly open after ectopic expression of p63 and KLF4 (Fig 2.4b, Supplemental Fig
2.2i), and 20% of shared sites became newly decorated by H3K27ac (Fig 2.4c, Supplemental Fig
8

2.2i). Direct comparison of specific shared p63/KLF4 bound peaks in basal keratinocytes to
fibroblasts, to fibroblasts + p63, and to fibroblasts + p63+KLF4 revealed highest similarity
between H3K27ac marked enhancers in keratinocytes and those in fibroblasts +p63+KLF4 (Fig
2.4d, Supplemental Fig 2.2j). These results show p63 and KLF4 function together to establish
chromatin structures concordant with those in basal keratinocytes.
Comparison of chromatin changes to gene expression revealed decreased chromatin
accessibility at downregulated genes, as well as at genes that remained unchanged
(Supplemental Fig 2.2j). Chromatin accessibility was increased only at promoters and enhancers
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of genes becoming upregulated upon conversion (Fig 2.4e, Supplemental Fig 2.2k).
Furthermore, H3K27ac decreased at genes that became downregulated, and profound increase
in H3K27ac in upregulated genes, reaching more than 20-fold increase in converting cells
compared to controls (Fig 2.4f, Supplemental Fig 2.2l). At the local level, a genome browser view
of the KRT14 locus exemplifies these dramatic changes in chromatin landscape and transcription
(Fig. 2.5a). In fibroblasts +p63+KLF4, establishment of enhancers occurred at intronic and
intergenic regions around KRT14. The establishment of these enhancers was accompanied by a
stark increase in KRT14 expression (Fig 2.5a). As mentioned above, IRF6 is a key gene for
CL/P, and KLF4 was also co-bound with p63 to the IRF6 enhancer with accompanying chromatin
changes (Fig 2.5b).

Figure 2.4: p63 and KLF4 co-establish keratinocyte specific enhancers. A) Venn diagram
showing p63 and KLF4 are cobound in 13488 loci in the genome. B) Graph of p63/KLF4 peaks
partitioned into open and closed chromatin according to peaks called from ATACseq showing
increased chromatin accessibility after 72 hours at co-bound sites. C) Pie charts showing stark

30

increase in chromatin accessibility and H3K27ac at p63/KLF4 peaks. D) Heat map showing
H3K27ac enrichment flanking p63/KLF4 peaks (+/- 2.5kb from peak center) shared in p63ChIPseq of basal keratinocytes, comparing fibroblasts, fibroblasts +p63, fibroblasts +p63+KLF4
and reanalyzed basal keratinocyte data from

8

E)F) Boxplots showing increased chromatin

accessibility and H3K27ac at p63/KLF4 sites near upregulated genes (* p-Value < 10E-10).

Figure 2.5: Local chromatin and transcriptional changes catalyzed by p63 and KLF4. A)B)
UCSC genome browser tracks showing de novo H3K27ac and ATACseq signal at enhancer and
promoter regions close to keratinocyte genes KRT14 and IRF6, as well as transcriptional
activation (grey highlighted box).

Overall, our results show p63 and KLF4 convert fibroblasts into keratinocyte-like cells via
co-establishment of keratinocyte-specific enhancers. Specifically, p63 alone was able to establish
epithelial enhancers to upregulate 32% of genes upregulated by p63 + KLF4 (710/2214
upregulated genes) (Fig 2.1f, Supplementary Table 2.1, e.g. IRF6, F11R, ITGA7). However,
importantly, both p63 and KLF4 were required to establish keratinocyte-specific enhancers and
upregulate their respective genes, such as KRT14, KRT6A and JAG2. Because fibroblasts do not
express p63, this trans-differentiation model constitutes a tractable system to investigate
mechanisms underlying wild type and mutant p63 function in keratinocyte enhancer specification
and to uncover key disease-specific processes. Because p63 represents a key transcription

31

factor driving epithelial specification and because p63 mutations are implicated in cleft lip palate
and other orofacial developmental anomalies, we focused on further characterization of p63.

2.2.3: Disease-specific p63 mutations found in patients with craniofacial malformations
show defects in enhancer establishment.
Heterozygous point mutations in the DBD and SAM domains of p63 have been shown to
lead to limb and craniofacial malformations in human patients
are likely to be deleterious due to loss of DNA binding

37–39

4–6

. While mutations within the DBD

, mutations within the SAM domain are

likely to lead to dysregulation of protein-protein interactions needed for epithelial lineage
specification

40–42

.

We selected two point mutations for this study: p63R304W (Fig 2.6a, orange), a point
mutation in the DBD occurring in patients with ectrodactyly ectodermal dysplasia cleft lip/palate
7

syndrome (EEC) and p63I537T(Fig 2.6a, blue), a point mutation in the SAM domain found in
39

patients with ankyloblepharon-ectodermal dysplasia and cleft lip/palate syndrome (AEC) . Since
characterized patients carry heterozygous p63 mutations, our homozygous model captures a
severe scenario, with mutation of all p63 molecules within a tetramer; this approach allows
investigation of substitution mutations in a simplified context.
We introduced p63R304W (mtDBD) or p63I537T (mtSAM) into our inducible conversion
system with co-expressed KLF4, for 72 hours (Fig 2.1a). Cellular immunofluorescence for KRT14
revealed defects in conversion for both mutants (Fig 2.6b). As expected, the deleterious effects of
mtDBD were most severe, showing no induction of KRT14 expression after 72 hours, whereas
mtSAM showed reduced KRT14 expression compared to WT p63 (Fig 2.6b). RNAseq revealed
that either substitution mutation poorly induced the top 15 genes upregulated by WTp63+KLF4,
including epithelial-specific genes KRT6A, GJB4, LAD1 and CDSN (Supplemental Fig 2.3a;
Supplementary Table 2.3). Further, among the 3367 differentially expressed genes in
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WTp63+KLF4, nearly all failed to be induced in the mtDBD+KLF4 compared to control fibroblasts
(Fig 2.6c). Hence, loss of p63 binding to DNA leads to complete loss of epithelial enhancer
establishment in fibroblasts and nearly abrogates differential gene expression [16/3367 genes
became upregulated (Supplementary Table 2.3)]. In contrast, mtSAM showed an intermediate
expression pattern between WT+KLF4 and control fibroblasts, indicating specific defects in
enhancer establishment and downstream epithelial gene induction (Fig 2.6c). Given this latter
interesting specificity in defects, we focused on the SAM mutant p63I537T to dissect which
deficiencies underlie the disease-specific phenotypes observed in AEC.

Figure 2.6: Disease specific p63 mutations found in patients with craniofacial
malformations show defects in converting fibroblasts to keratinocyte-like cells. A) Linear
schematic of p63, showing domain structure and selected patient derived mutations B)
Immunofluorescence of p63 and KRT14 in fibroblasts + fibroblasts +KLF4 and +WTp63, mtDBD
or mtSAM showing KRT14 is not upregulated when the DBD is mutated and induction of KRT14
is lower in mtSAM C) Heatmap of z-scored 3367 differentially expressed genes (fold change >
1.5 and FDR < 0.05) between fibroblasts control and fibroblasts +p63+KLF4 showing mtDBD has
almost no change in transcriptional profile and mtSAM shows a transcriptional profile in between
fibroblasts ctrl and fibroblast +WTp63+KLF4.
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We investigated the effect of the mtSAM on p63 binding genome-wide.

Among the

13488 p63/KLF4 DNA binding sites in WTp63+KLF4 conversion (Fig 2.4a), most (71%; 9513) of
the p63 binding peaks were retained in mtSAM+KLF4, and only 29% (3975) of p63 bound peaks
were lost (Supplemental Fig 2.3b). The partial loss of mtSAM binding to DNA may be due to
43

increased protein aggregation caused by SAM domain mutations within p63 . However, despite
largely maintaining binding to DNA (Fig 2.7a, left panel), there was no increase in chromatin
accessibility (Fig 2.7a, ATAC-seq) at retained mtSAM/KLF4 sites (Fig. 2.7a, 2.7b left).
Furthermore, while most H3K27ac peaks were retained (Fig 2.7a), overall the amplitude of
H3K27ac peaks increased only modestly compared to WT+KLF4 (Fig 2.7b right). Taken together
with the observation that KLF4 binding is retained in the majority of these peaks (Fig 2.7a), these
results suggest that the SAM domain of p63 is crucial for chromatin accessibility and
establishment of H3K27ac in epithelial enhancer specification.
We examined how these chromatin changes affect downstream gene regulation of the
closest genes to p63/KLF4 bound sites. RNA-seq analysis revealed 50% of genes upregulated by
p63/KLF4 were no longer upregulated in mtSAM (~1200 genes; Fig 2.7c), including key genes
involved in craniofacial development, such as GRHL3, JAG2, LAMB3 and IRF6 (Supplemental
Figure 2.3c, Supplementary Table 2.3). We assessed whether genes that were able to maintain
activation in mtSAM/KLF4 had pre-existing enhancers, which might explain their continued
expression.

Indeed, genes that maintained expression with mtSAM/KLF4 were near pre-

established and H3K27ac pre-decorated enhancers (Fig 2.7d left). In contrast, genes near newly
established enhancers failed to be upregulated in mtSAM/KLF4 (Fig 2.7d right). Additionally,
~200 genes were aberrantly upregulated in mtSAM/KLF4, including genes involved in craniofacial
development in non-epithelial cell types, e.g. BMP2, VAX2 and GAD1 (Fig. 2.7b, Supplementary
Table 2.3).
At the local level, FOXN1 (Fig 2.7e), IRF6 (Fig 2.7f) and LAMB3 (Supplemental Fig 2.3d)
showed defects in enhancer establishment despite retained binding of mtSAM and KLF4. In
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particular, chromatin remained largely closed with mtSAM (in red highlighted box) and reduced
H3K27ac flanking these sites, and these defects in establishing normal enhancer chromatin
landscape lead to profound failure in upregulating associated genes FOXN1, IRF6 and LAMB3
(Fig 2.7e,2.7f and Supplemental Fig 2.3a,2.3c).

Figure 2.7: Mutations in the SAM domain of p63 found in AEC syndrome show defects in
establishing enhancers and downstream activation of epithelial genes. A) Heatmap showing
a stark reduction in chromatin accessibility (ATACseq signal) in mtSAM compared to WTp63,
decreased H3K27ac and retained p63 and KLF4 binding. B) Box plots showing no increase in
chromatin accessibility for mtSAM, as well as reduced enrichment of H3K27ac flanking p63/KLF4
peaks. C) Venn diagram showing over 1000 genes are no longer upregulated in mtSAM+KLF4

35

and about 200 genes are upregulated de novo by this mutant. D) Box plots showing RNA-seq
signal of genes close to p63/KLF4 retained peaks separated into peaks at pre-established
enhancers in fibroblasts and newly established enhancers after ectopic expression of p63/KLF4.
E)F) UCSC genome browser tracks showing defects (red boxes) in establishing open chromatin
and inducing gene expression at FOXN1 and IRF6.

Together our chromatin and transcription data show a dramatic difference in the roles of
the DBD and the SAM domains of p63. The DBD is essential for enhancer establishment due to
loss of function in DNA binding. Importantly, while the SAM mutant is able to bind to DNA, there
are profound defects in both chromatin opening and establishment of H3K27ac, correlating with
defective upregulation of proximal epithelial genes, Thus, because the SAM domain mutant I537T
is found prominently in AEC syndrome, our results identify a potential explicit molecular
mechanism, in which mtSAM drives pathogenesis through aberrant enhancer establishment
(despite maintaining DNA binding) leading to low levels of specific critical craniofacial genes,
such as IRF6, JAG2 and GRHL3.

2.2.4: p63 regulates expression of critical genes associated with cleft lip/palate.
5,6

While EEC and AEC are uncommon syndromes , orofacial clefting is a key feature of
11

these pathologies and clefting is a common developmental defect throughout the world . Mouse
genetic models (including knockouts of Trp63 and Irf6) have been crucial in understanding lip and
palate development, however they do not fully recapitulate defects observed in human
patients

15,16

. To date, 16 genes have been strongly implicated in nonsyndromic cleft lip+/- cleft

palate (nsCL/P) via related phenotypes in mouse KO and knock down (KD) studies

44

(Supplementary Table 2.4a). Of the 16 reported genes, 5 were upregulated in our transdifferentiation model (ESRP1, IRF6, FOLR1, FGFR8, WNT9B) (see Fig 2.5b, Supplemental Fig
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2.2d, Supplementary Table 2.2 and Supplementary Table 2.4a), and ESRP1, IRF6 and FOLR1
also showed robust dysregulation in mtSAM (Supplemental Fig 2.4a). Importantly, of these
genes, only IRF6 was previously reported to be regulated by p63

21,27,28

, providing novel

mechanistic insights into clefting pathogenesis via p63 mtSAM from our genome-wide study.
Genetic Association Database studies

45

of genes upregulated in our trans-differentiation

model identified cleft lip and/or cleft palate as the most highly enriched disease associated
category (Fig 2.8), with 76 associated genes identified, including genes known to cause nsCL/P
(e.g.WNT9B, JAG2, and CDH1; full list in Supplementary Table 2.4b)

29,35,46,47

. Many of these 76

genes have been identified as causal for orofacial clefting through human syndromes and family
studies, while others are in proximity of SNPs involved in CL/P but are not known to be causally
or functionally involved with orofacial clefting.

Figure 2.8: Transdifferentiation model shows genes upregulated by p63 and KLF4 have
been associated to cleft lip/palate. Genetic association database results showing cleft lip/cleft
palate is the most enriched disease category among the 2213 genes upregulated (fold change >
1.5 and FDR < 0.05) by p63 and KLF4.
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To date, genome-wide association studies (GWAS) and other approaches have identified
40 human risk loci for nsCL/P with conclusive evidence (Supplementary Table 2.4c)

14,17–20

. These

40 loci are estimated to explain about 25% of the heritability reported for nsCL/P. However, the
causative genes and mechanisms at the majority of these loci are unknown. While previous
14

studies have shown the importance of neural crest cells in CL/P development , different tissue
systems are expected to contribute to this complex disease. In particular, keratinocytes from
patients with CL/P have recently been reported to display differentiation defects

48–51

. Based on

the key observation that p63+KLF4 establish enhancers to regulate keratinocyte specific genes,
including critical craniofacial genes (see Supplemental Fig 2.2d, Supplementary Table 2.2), we
investigated the genes located within the topologically associated domain (TAD)

52,53

overlapping

each of the 40 risk loci. The reasoning to examine gene association within TADs is because gene
regulatory enhancer-promoter contacts occur primarily within TADs

52–54

. We found that within the

associated TAD of 17 of these risk loci, at least 1 gene, and a total of 37 genes were upregulated
in our trans-differentiation model (Fig 2.9, Supplementary Table 2.4c). We conclude that crucial
regulatory interactions occur within TADs encompassing genes induced by p63/KLF4.

Figure 2.9: p63 and KLF4 upregulate genes within TADs containing cleft lip/palate risk loci.
40 identified risk loci for cleft lip/palate indicated by black lines at the respective chromosomes
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with dark blue circles at TADs containing at least 1 gene upregulated by both p63 &
KLF4(respective genes in dotted triangles).

To analyze whether any of the 37 genes (Fig 2.9b) located at the risk loci and/or their
enhancer regions might contribute to nsCL/P, we used SNPs and their p-values from a recent
GWAS

on

nsCL/P

14

to

compute

gene-based

association

p-values

using

55

MAGMA (Supplementary Table 2.4d). We first validated our approach by examining genes
upregulated by p63+KLF4 within and outside of the 40 risk loci that have been shown to cause
nsCL/P

21,47,56

. We identified significant p-values for known causal genes within the 40 risk loci,

such as in the 1q32 locus (IRF6), 17q21 (WNT9B) and 8q22.1 (ESRP1) loci (Fig 2.10, red). Our
approach also identified significant p-values for known causal genes outside of the risk loci,
including JAG2, CDH1, and CTNND1

29,46,57

(Fig 2.10, red with *).

Figure 2.10: p63 regulates expression of critical genes associated with orofacial clefting.
List showing association values of top 10 genes calculated by gene-based analysis with MAGMA
as implemented in FUMA
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in the following categories: (red) genes known to cause CL/P with *

marking genes outside of the known 40 risk loci; (green) CL/P candidate genes located at 40 risk
loci with significant (p<0.05) association to CL/P and (blue) new candidate genes associated with
CL/P outside of known risk loci.
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Within the 40 risk loci we identified 10 candidate genes upregulated by p63 with
significant gene based association p-values to nsCL/P (p-value<0.05), including SEMA4D,
BEST3, ZFP36L2, and KRT4 (Fig 2.10, green). Interestingly, in three of the risk loci, our data
point towards a risk gene for nsCL/P that is different from the gene previously suggested: At
58

2p21, THADA was previously suggested to be the risk gene , our data suggests it is ZFP36L2
59

(p<0.05) (Fig 2.10, green with *), a gene shown to play a role in basal keratinocytes . At 2p25.1
KLF11 had been suspected to be the nsCL/P risk gene, our data suggests it is GRHL1 (p<0.5) a
close family member of GRHL3, a well-established risk gene for cleft palate

60,61

. Further, at risk

loci 9q22.2 our data prioritize SEMA4D (p<10E-05) (Fig 2.10, green with *) instead of
61

GADD45G , as the probable nsCL/P risk candidate.
Finally, to identify novel risk loci and novel causal candidate genes for nsCL/P, we
extended our gene based association p-value study to genes upregulated in our transdifferentation model outside of the known 40 risk loci. We identified 111 novel candidate genes
showing high association to nsCL/P (p-values <0.05 computed as above, Supplementary Table
2.4d). Several identified genes, including ZNF296, CPNE9, ITGB4, and ZNF750 (Fig 2.10, blue)
play key roles in epithelial cells but have no known role in CL/P. Regional association plots for
ZNF296 and CPNE9 demonstrating the local association structures at these genes in the GWAS
data reveal SNPs with nominal statistical significance at each of these genes and also in the
surrounding non-coding areas (Fig 2.11a,b). The location of these SNPs suggest that common
genetic variants within or near these genes regulated by p63 might alter gene function or
expression and, thus, may contribute to nsCL/P, but the genes have escaped detection in genetic
studies due to lack of statistical power (such as sample size).
Overall, our trans-differentiation model in human cells provides an orthogonal approach
to identify candidate genes in nsCL/P directly regulated by p63. Indeed, even at established risk
loci, we have used our approach to find key p63-regulated genes, as the most likely CL/Passociated genes (e.g. ESRP1, GRHL1, RHPN2, and ARID3B). Further we use this approach to
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identify new nsCL/P specific candidate genes and the enhancers that regulate them (e.g.
ZNF296, CPNE9, ITGB4, and TDRP).

Figure 2.11: Transdifferentiation model reveals novel nsCL/P candidate genes and the
enhancers that regulate them. A)B) Regional association plots of ZNF296 and CPNE9,
showing nsCL/P associated SNPs with nominal significant gene-based p-value (<0.05) within the
genes and up to 200kb away from transcription start sites.
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2.2.5: SNPs associated with cleft lip/palate are highly enriched in enhancers established
by p63 and KLF4
GWA studies of SNPs have identified several genetic variants strongly associated to
nsCL/P

14,17–20

. Many of these disease-associated SNPs are located outside of exons, thus

suggesting a gene expression regulatory role, such as enhancers and promoters. Since orofacial
clefting is a major phenotype in patients with point mutations in p63, and, as we show here, since
p63 plays a key role in establishing epithelial enhancers, we explored potential overlap between
p63 binding sites and nsCL/P-associated SNPs identified in GWA studies. We curated three lists
of p63 binding sites: (A) all p63 peaks in fibroblasts +p63; (B) all p63 peaks in fibroblasts
+p63+KLF4; (C) p63/KLF4 shared peaks in fibroblasts +p63+KLF4 (i.e. a subset of (B)). Using
the same GWAS dataset as above

14

62

and the enrichment-tool GREGOR , we determined that list

C - p63 peaks co-bound by KLF4 - showed strongest enrichment of nominal significant (p<0.05)
nsCL/P SNPs (Fig 2.12a). We focused on H3K27ac flanking these sites as a mark of active
enhancers, partitioning H3K27ac peaks into enhancers that are preestablished (already marked
by H3K27ac in fibroblasts) or into new enhancers (only become marked by H3K27ac after
fibroblast to keratinocyte-like conversion) (see Fig 2.4c, 2.4d). Enrichment analysis showed
significant enrichment (p<0.05) of nominal significant nsCL/P SNPs only for newly established
enhancers (Fig 2.12a).
Based on the results from GREGOR we performed colocalization analysis of nsCL/P
14

SNPs, focusing on the p63/KLF4 shared peaks . This analysis further accounts for the strength
of association to nsCL/P of each SNP, with highly associated SNPs contributing to a lower
overall co-localization p-value (see Methods). We observed significant colocalization (p-value
<0.05) for p63/KLF4 peaks in which active enhancers are established (newly marked by
H3K27ac), whereas shared p63/KLF4 peaks at preestablished enhancers and peaks without
H3K27ac did not achieve statistical significance (Fig 2.12b).
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We next focused on H3K27ac peaks - which are broader than p63/KLF4 peaks - because
SNPs close to, but outside of p63/KLF4 peaks, might be in linkage disequilibrium and contribute
to risk of CL/P. We performed colocalization analysis of nsCL/P SNPs in H3K27ac peaks in
control fibroblasts, in preestablished enhancers, and in new enhancers flanking p63/KLF4 peaks
(Fig. 2.12c). Here only enhancers newly established by p63/KLF4 showed strong colocalization
(p-value <10E-4) (Fig 2.12c), confirming the results obtained in the GREGOR analysis.

Figure 2.12: SNPs associated with non-syndromic cleft lip with or without cleft palate are
highly enriched in enhancers established by p63 and KLF4. A) GREGOR analysis showing
p63/KLF4 shared peaks (green) and newly established H3K27ac (orange) flanking these peaks
are significantly (p<0.05) enriched for SNPs associated to nsCL/P. B) Co-localization of shared
p63/KLF4 peaks at inactive/preestablished/new enhancers, with nominal significant nsCLP
associated GWAS SNPs. Graph shows only p63/KLF4 peaks flanked by de novo H3K27ac peaks
are enriched for nsCL/P associated SNPs. C) Co-localization of H3K27ac peaks with nominal
significant nsCLP associated GWAS SNPs. Graph shows only new enhancers in converted cells
flanking p63/KLF4 peaks are significantly enriched for nsCL/P associated SNPs.
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Genome browser views overlaid with nsCL/P SNPs allowed visualization of the high
colocalization of SNPs at p63/KLF4 peaks and newly established enhancers (ATAC-seq and
H3K27ac peaks) close to MAFB (Fig 2.13a), at the known 8q24 risk locus

63

(Fig 2.13b), at the

nsCL/P causing gene IRF6 (Supplemental Fig 2.5a) and near RHPN2 (Supplemental Fig 2.5b).
Importantly, the genes downstream of these regulatory elements are activated in our transdifferentiation model (see RNA-seq in Fig 2.13a,b and Supplementary Fig 2.5a,b), indicating they
are upregulated by establishment of new enhancers by p63/KLF4.

Figure 2.13: Enhancers established by p63 and KLF4 at MAFB and the 8q24 locus are
enriched for SNPs associated with nsCL/P. A) and B) Overlay of SNPs and UCSC genome
browser tracks highlighting in orange that p63/KLF4 peaks strongly colocalize with highly
associated nsCL/P SNPs near MAFB and the known 8q24 locus, in grey binding of both proteins
at promoters.

Overall, GREGOR analysis and colocalization results show enhancers established by
p63/KLF4 are highly enriched for SNPs associated with nsCL/P. These SNPs likely affect
downstream expression of epithelial specific genes and lncRNAs required for proper lip and
palate development, as observed with IRF6 and mutations in an upstream regulatory element of
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this gene established by p63 . Thus our unbiased trans-differentiation model in conjunction with
GWAS data provides an independent method to identify driver genes. The method also provides
novel mechanistic insights into how nsCL/P-related SNPs might be regulating pathogenesis via
disruption of p63/KLF4 binding sites crucial for enhancer establishment and downstream gene
regulation.

2.3: Discussion
Here we report a trans-differentiation model as a novel approach to determine the role of
p63 in craniofacial development. We show that p63 can establish epithelial enhancers to regulate
downstream genes and that this process is disrupted when p63 carries mutations derived from
human disease. In particular, our results show a novel mechanism underlying pathogenic p63
mutations, in which failure to open and establish enhancers leads to transcriptional dysregulation.
We integrate our epigenomic data with GWAS datasets derived from nsCL/P patients to identify
novel CL/P candidate genes regulated by p63. We also uncover strong enrichment of nsCL/Passociated SNPs at enhancers established by p63, providing mechanistic insight into how these
SNPs lead to human pathogenesis.
A key role of transcription factor p63 in mediating epidermal commitment, development,
and differentiation has been extensively demonstrated through mouse models and causative
point mutations in human disease. In mice, knockout of p63 leads to developmental and
morphological defects in the squamous epithelia and epidermis, causing abnormal craniofacial
2,3

development, truncated limbs, and loss of salivary glands, hair follicles, and teeth . To date, how
p63 engages and modifies chromatin to promote normal development during these early stages
is still being elucidated. Here, we report key observations that p63 can establish enhancers and
that defects in this process may underlie human craniofacial malformations.
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Previous studies of p63’s engagement with chromatin have focused on its role in
keratinocyte differentiation

8,10,51,64,65

, while de novo engagement with chromatin has not been

extensively addressed due in part to lack of tractable human models. Thus, to examine the first
encounter of p63 with chromatin, we expressed p63 ectopically in a temporally controlled manner
in human BJ fibroblasts, a cell line that does not express p63. We show p63 establishes
enhancers to upregulate epithelial and inflammation genes. We next developed an inducible
trans-differentiation model based on published reports showing p63 co-expressed with KLF4 can
34

convert fibroblasts into keratinocyte-like cells . We determined that co-binding of p63 and KLF4
leads to robust establishment of enhancers that correspond remarkably well to bone fide
enhancers in basal keratinocytes. Thus, this model system recapitulates the epigenetic conditions
of early epithelial development.
Mutations in the p63 DBD in EEC patients have been previously shown to cause loss of
downstream transcriptional activation of known p63 targets

40,51,66

. Further studies showed that

p63 mutations in AEC also disrupted transcription and caused p63 aggregation

43,40–42

. In

particular, it has been proposed that aggregation of p63 in AEC leads to decreased binding of
p63 to its DNA targets and that this is a key underlying disease mechanism

43

. However, it

remains unclear how enhancer regulation by p63 is altered by substitution mutations. Our
approach shows that one prevalent substitution mutation in the DBD leads to complete loss of
p63 binding to chromatin and loss of enhancer establishment. On the other hand, one frequent
substitution mutation in the SAM domain largely retains DNA binding but results in defects in
chromatin opening, causing dysfunctional enhancer establishment and defective upregulation of
key craniofacial genes. These results suggest the SAM domain is involved in recruiting chromatin
remodelers to displace nucleosomes and establish open chromatin, in line with previous reports
suggesting p63 and the BAF complex cooperate to open chromatin during epidermal
64

differentiation . Further experiments are required to identify proteins interacting with the SAM
domain of p63 to perform these functions. However, our results point towards a novel function of
the p63 SAM domain, as well as a novel molecular mechanism underlying AEC.
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While EEC and AEC are relatively rare, one phenotype of both syndromes is cleft lip
11

palate, which also occurs in the absence of p63 mutations in 1:700 births .
between p63 and CL/P has previously been proposed

32,67,68

A connection

, however, these studies were largely

carried out in mice, a model in which KO and KD of p63 does not accurately recapitulate clefting
2,3

of the lip or palate . This could be in part due to extensive rewiring of the p63 response element
network between mouse and human, as well as human specific craniofacial enhancers that were
recently reported
71

69,70

. Further, mouse models of known disease-causing genes such as IRF6,

PVRL1 , and CDH1
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in human also fail to recapitulate clefting of the lip

15,16,35,44

, suggesting

stark differences in these processes between species and highlighting the need for orthogonal
human approaches. In humans, GWAS and other approaches have identified 40 human risk loci
for nsCL/P with conclusive evidence. These 40 loci represent about 25% of heritability in nsCL/P
cases reported, however at the majority of these loci, the causative variants and mechanisms are
unknown, due in part to a lack of mechanistic data within non-coding regions. Thus, by integrating
epigenomic datasets from our trans-differentiation keratinocyte model with GWAS datasets, we
gained novel insights into molecular mechanisms underlying nsCL/P.
Overlapping of our results with GWAS datasets from nsCL/P identified key known
candidate genes regulated by p63 and newly established enhancers at known risk loci, including
IRF6 in the 1q32 locus and WNT9B at 17q21.32. Importantly, we identified ZFP36L2 and GRHL1
at 2p21 and 2p25.1 respectively as the lead risk nsCL/P genes despite previous reports focusing
on other genes in those loci

58,61

. Our data also prioritized ESRP1 and SEMA4D, known genes in

epithelial regulation, as nsCL/P risk candidates at 8q22.1 and 9q22.2 loci in which the risk genes
had not been identified. Knockout studies of ESRP1 in particular showed full penetrance of CL/P
56

in mice . Further, by combining GWAS datasets with genes upregulated in our transdifferentiation model, we identified over 100 new candidate genes and risk loci for nsCL/P
validation studies, including ZNF296, CPNE9, and ITGB4. These genes play important roles in
epithelial cells but their role in nsCL/P had, prior to our study, been unknown.
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In addition to identifying genes downstream of p63, our analysis also identified the
enhancers that regulate them. For instance, FOLR1 and FOLR3 were both upregulated in our
trans-differentiation model following establishment of upstream enhancers by p63 and KLF4.
72

Knockout of the mouse homolog of FOLR1 gene was shown to lead to orofacial clefting ;
however, mutations in these genes have not been found in humans with CL/P. It is possible that
previously uncharacterized mutations at the enhancers of these genes may increase risk of CL/P,
which could be mitigated by folic acid supplementation, as is the case in mouse models with KO
72

of folbp1 .
Finally, using two different co-localization analyses, we found that enhancers established
by p63+KLF4 are enriched for SNPs associated with nsCL/P, providing a novel molecular
mechanism for how these SNPs may contribute to disease at a molecular level. For instance, at
the nsCL/P risk loci 20q12, MAFB has been proposed to be the main risk gene for nsCL/P

12,73

.

However, no functional or mechanistic data has supported this claim. Our integrated data shows
p63 and KLF4 co-bind and establish enhancers upstream of MAFB, leading to robust de novo
expression of MAFB. These enhancers are enriched for nsCL/P associated SNPs, providing a
novel mechanism underlying how these SNPs may affect proper expression of MAFB during lip
and palate development. Another example is the known 8q24 risk locus, which shows the
strongest effect size across populations of Asian and European origin

63,74

. Previous reports

conducted in murine models suggested that this region contains enhancers important for MYC
75

regulation ; however, deletion of this region resulted in clefting of the lip or palate in less than 7%
of murine embryos, despite robust downregulation of MYC. Our data shows this region contains a
number of p63+KLF4 bound and established enhancers that are enriched for SNPs associated
(p<5.0E-8) with nsCL/P. Further, we show establishment of enhancers in this region lead to
upregulation of a long noncoding RNA LINC00977 which is not present in mice. In human
keratinocytes, it was previously observed that knockdown of p63 leads to downregulation of
76

MYC . Thus, it is possible that p63 regulates enhancer establishment at 8p24 to upregulate
LINC00977 and modulate MYC expression during lip and palate development. While mechanistic

48

experiments are necessary to confirm this, our data provide novel candidate disease mechanisms
underlying nsCL/P.
Taken together, our findings address how p63 binds and remodels chromatin with its first
encounter, identifies and prioritizes nsCL/P candidate genes and the enhancers that regulate
them, and provides new explanations for how p63 mutations and SNPs associated with nsCL/P
underlie disease.

2.4: Materials and methods
2.4.1: Cell culture
BJ foreskin fibroblasts (CRL-2522) were obtained from American Type Culture Collection
(ATCC), and were cultured in a 37˚C incubator at 3% oxygen, in tissue culture medium containing
DMEM with 10% FBS, 100µg/ml streptomycin and 100 units per ml penicillin.
2.4.2: Lentivirus and retrovirus infection
Stable cell lines were made by lentivirus and retrovirus infection, as previously
74

described . Tetracycline On System was introduced in two steps. First the reverse tetracyclinecontrolled transactivator (rtTA) was introduced via lentivirus Lenti CMV rtTA3 Blast (w756-1)
(Addgene plasmid #26429). Lentivirus was transfected with packaging plasmids to HEKT293T
cells, viral supernatant was filtered through a 0.45µm filter, supplemented with 8µg/ml polybrene,
and mixed with trypsinized BJ cells for 24 hours. Cells were selected for 1 week using blasticidin
at 4µg/ml.
We then cloned ∆NP63alpha-Flag (Addgene plasmid #26979) and ∆NP63α-Flag cloned with a
T2A self-cleaving peptide linker to human KLF4 (plasmid #19777) into a retroviral construct
pRetroX-TRE3G-puro construct. We introduced point mutations (I537T and R304W) into p63 via
Quick Change II site directed mutagenesis from Agilent (Catalog # 200523). Retrovirus constructs
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were transfected to Phoenix packaging cell line, purified and used as described above. Infected
cells were selected with puromycin for approximately a week.

2.4.3: Trans-differentiation
BJ stable cell lines infected with rtTA and either an empty pRetrox-TRE3G vector,
pRetrox-TRE3G-∆NP63α-Flag or pRetrox-TRE3G-∆NP63α-Flag-T2A-hKLF4 were induced for 72
hours using 1ug/ml doxcycycline replenished every 24 hours. A low dose of hydroxyurea (HU)
1mM was added after 24 and 48 hours, as we observed this improves conversion without
affecting control cells. Cells were then collected for western blot, ATAC, RNA and ChIPseq.
2.4.4: Western Blot
Cells were lysed in RIPA buffer containing 1% NP-40, 150mM NaCl, 50mM Tris-Cl, pH
8.0 and 1% SDS supplemented with cOmplete, EDTA-free protease inhibitor (Roche
11873580001). Protein concentration was determined by BCA protein assay (Life technologies,
#23227), after which equal amount of proteins were loaded and separated by polyacrylamide
gels. Proteins were then transferred to nitrocellulose membranes. Antibodies used in this study
were as follow: Flag (Sigma, M2, F1804), hKLF4 (R&D Systems, AF3640), p63 (Cell Signaling
Technology, D2K8X), GAPDH (Fitzgerald, 10R-G109a) and KRT14 (Abcam, ab7800).
2.4.5: Immunofluorescence
Trans-differentiated and control fibroblasts grown on cover glasses were fixed in 4%
paraformaldehyde in PBS for 30min. Cells were then washed twice with PBS, and permeabilized
with 2.5% Triton X-100 in PBS for 10min. After two washes, cells were blocked in 10% BSA in
PBS for 1 hour at room temperature. Cells were then incubated at 4˚C overnight with primary
antibodies in 5% BSA in PBS with 0.1% Tween 20 (PBST). Primary antibodies used were: Flag
(Sigma, M2, F1804), hKLF4 (R&D Systems, AF3640), p63 (Cell Signaling Technology, D2K8X)

50

and KRT14 (Abcam, ab7800). The next day, cells were washed 4x10min with PBST, followed by
incubation with Alexa Fluor-conjugated secondary antibodies (Life Technologies) in 5% BSA in
TBST for 45 minutes at 37˚C. Cells were then washed 3x10min in PBS, incubated with 0.5µg/ml
DAPI in PBS for 5 min, and washed twice with PBS. The slides were then mounted using
VECTASHIELD antifade mounting medium (H-1000, vector Laboratories) and incubated
overnight in the dark at room temperature. The slides were then imaged with a Nikon Eclipse 80i
fluorescent microscope.
2.4.6: Chromatin immunoprecipitation and RNA preparation
Trans-differentiated and control BJ fibroblasts (population doubling 20-30) were
crosslinked with formaldehyde (1% final) for 5 min at room temperature or lysed in TRIzol
(ThermoFischer Scientific, #15596018) and snap frozen for RNA isolation. Crosslinked cells were
quenched with glycine (125mM final) for 5 min, followed by 2 x washes in cold PBS. Nuclei were
75

then isolated from 20 million cells as previously described , and chromatin was sheared to
250bp average size using a Covaris S220. Immunoprecipitations were performed using 500µg
sheared chromatin lysate and 5 µg antibodies preconjugated to Protein G beads (Invitrogen):
H3K27ac (Active Motif, 39133), Flag (Sigma, M2, F1804) and hKLF4 (R&D Systems, AF3640).
ChIP reactions were incubated for 16 hours at 4˚C with rotation and then washed 4x in wash
buffer (50mM HEPES-HCl pH 8, 100mM NaCl, 1mM EDTA, 0.5mM EGTA, 0.1% sodium
deoxycholate, 0.5% N-laurylsarcosine), followed by 1 wash in ChIP final wash buffer (1xTE,
50mM NaCl). Immunoprecipitated DNA was eluted from washed beads, reverse crosslinked
overnight, purified and used to construct libraries. Snapfrozen RNA samples were further
extracted using chloroform and QIAGEN RNeasy Mini Kit (#74106) including DNase digestion.
Purified RNA was then reverse transcribed to cDNA using High Capacity cDNA Reverse
Transcription Kit from Applied Biosystems (4368814), cDNA was then quantified and used to
construct sequencing libraries.
2.4.7: ChIP/RNA sequencing and data analysis
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Sequencing libraries for ChIP experiments were prepared using NEBNext Ultra reagents
(New England Biolabs). All ChIP samples and input were double-end sequenced on an Illumina
NextSeq 500. Reads were mapped to the reference human genome assembly GRCh37/hg19
using Bowtie2 (maximum fragment size set to be 2000 bp). Properly aligned, non-duplicated pairs
were retained for peak calling using MACS2 (q-value cutoff set to be 0.01). Fragment pileup per
million reads for each ChIP library and corresponding input were also generated and subtracted
by MACS2 for visualization. Only overlapping peaks shared by biological replicates were used for
analysis.
Poly(A) + RNA was isolated using double selection with poly-dT beads, followed by first
and second-strand synthesis. Reads were mapped to the reference human genome assembly
GRCh37/hg19 using splice-aware tool STAR (maximum fragment size set to be 2000 bp).
Alignments with a MAPQ score over ten were counted towards RefSeq genes using
featureCounts (default parameters). Fragment pileup per ten million reads for each RNA library
were generated by BedTools (“genomecov -split -bg -scale”) and UCSC tool package
(“bedGraphToBigWig”). Pairwise differential expression analysis was implemented using R
package DESeq2 with FDR cutoff set to be 0.05 and fold-change cutoff set to be 1.5.
2.4.8: Assay for transposase-accesible chromatin (ATAC-seq)
ATACseq experiments were performed as previously described

76

using 100,000 cells and

5µL Tn5 transposase (Nextera XT Kit, Illumina) to tagment intact nuclei. Reads were mapped to
the reference human genome assembly GRCh37/hg19 using Bowtie2 (maximum fragment size
set to be 2000 bp). Properly aligned, non-duplicated pairs were retained and reads mapped to
mitochondria or ENCODE blacklist regions were excluded. For peak calling, we adjusted the read
start sites to represent the center of the transposon binding event (all reads aligning to the +
strand were offset by +4 bp, and all reads aligning to the - strand were offset -5 bp). Broad peaks
were called using MACS2 (q-value cutoff set to be 0.01). Fragment pileup per million reads for
each ATAC library were also generated by MACS2 for visualization. Similar to the ChIP-seq data,
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only overlapping peaks shared by biological replicates were used for analysis. To acquire subnucleosomal peaks, only fragments shorter than 120 nt were used.

2.4.9: Gene ontology analysis
GO terms of differentially regulated genes were determined using DAVID. We selected
the top 10 GO categories based on the lowest FDR.
2.4.10: Intersection
All p63 peak sets were combined by taking the union using BedTools (“bedtools merge”)
and categorized into different subsets based on whether they overlap with ATAC-seq or ChIP-seq
peaks (overlap by at least 1bp). Peaks were annotated to genes by the nearest RefSeq TSS
using HOMER (default parameters for “annotatePeaks” command). Motif analysis was
implemented using HOMER (“findMotifsGenome -size given”).
2.4.11: Statistical analysis
Metaplots and heatmaps centered around any peak set were generated using DeepTools
(“computeMatrix” and “plotHeatmap”). ChIP-seq or ATAC-seq signal over each peak region was
computed using Bwtool (unit: per million reads per kb) in order to generate boxplots and bar
graphs, and Mann-Whitney test was applied unless otherwise specified.
2.4.12: Analysis of GWAS-data for nsCL/P
GWAS-data for nsCL/P were retrieved from a previously published study

14

which had

included 399 cases, 1.318 controls and 1.461 case-parent trios. The SNP data comprised about
8.01 million common variants at a minor allele frequency (MAF) > 1%. All analyses for the
present manuscript were performed using the overall data, i.e., without stratification for ethnicity.
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2.4.13: Gene-based p-values.
While single variants alone might be statistically underpowered to show significant
effects, their contribution in sum can be analyzed by aggregating individual variants within a
predefined region (for instance, genes). Based on the p-values obtained from the nsCL/P GWAS
we used MAGMA (v1.06)
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a principal-component-based regression framework that allows for

gene-based analysis. We run the gene-based analysis for the p63 upregulated genes (n=250) as
implemented in the FUMA online tool (Functional Mapping and Annotation of Genome-Wide
73

Association Studies) platform (v1.3.2) , with default parameters (SNP-wide mean model) and
with the 1000 Genome Phase3 as reference panel. In the gene set analyses, curated gene sets
and GO terms from MsigDB are tested. For FUMA (≥ v1.3.1), 10655 gene sets (curated gene
sets: 4738, GO terms: 5917) from MsigDB v6.1 are used. Bonferroni correction was performed for
the all tested gene sets.
2.4.14: Enrichment analyses
To evaluate the enrichment of all nominal significant nsCL/P GWAS SNPs
selected regulatory elements, the GREGOR (v1.4.0)
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in à priori

software tool was used. Selection of the

regions was performed based on the presence of p63 and/or KLF4 and/or H3K27ac peaks. For
analysis of overlay of specific SNPs to specific elements, a colocalization approach was
14

performed as previously suggested . Briefly, SNPs were mapped to either “positive regions” (i.e.,
in p63+KLF4 +/- H3K27ac binding regions) or “negative regions” (all others) and then grouped
into nine categories 10

-k+1

-k

-8

≥ P > 10 for k = 1, . . ., 8 and 10 ≥ P. The frequencies of SNPs being

located in the positive regions and those outside the annotated regions were counted within each
category. The one-sided Cochran-Armitage trend test was applied in R environment with function
prop.trend.test of stats package to test for an enrichment of smaller P-values within annotated
regions on the basis of the resulting 9×2 contingency table.
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2.5: Supplemental Figures

Supplemental Figure 2.1: Ectopic expression of p63 in fibroblasts leads to establishment
of enhancers and downstream upregulation of inflammation and epithelial genes. A)
Western blot showing p63 ectopically expressed in fibroblasts reaches an expression level
comparable to endogenous levels observed in undifferentiated normal human epidermal
keratinocytes after 48h B) Alluvial plot depicting changes in chromatin state after ectopic
expression of p63 at p63 bound peaks for chromatin transitions with >200 peaks. C) Heatmap
showing high overlap between newly accessible chromatin (ATACseq) in fibroblasts + p63 and
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published MNaseSeq in human fibroblasts . D) Heatmap showing 1479 downregulated genes in
fibroblasts + p63 compared to control and GO categories enriched among downregulated genes.
E)F) Boxplots showing increased chromatin accessibility and H3K27ac across downregulated,
unchanged and upregulated genes in fibroblasts + p63, with the highest fold change for
upregulated genes (*p-Value<10E-5, **p-Value<10E-16). G) UCSC genome browser tracks
showing transcriptional activation of ITGA7 and de novo H3K27ac and ATACseq signal within
introns of ITGA7 in fibroblasts with ectopic expression of p63 (grey highlighted boxes)

Supplemental Figure 2.2: Ectopic co-expression of p63 and KLF4 leads to establishment of
keratinocyte specific enhancers and upregulation of epithelial genes. A) Western Blot
showing robust co-expression of p63 and KLF4 in the inducible trans-differentiation model
(fibroblasts+p63+KLF4) B) Western Blot showing KRT14 is only upregulated when both p63 and
KLF4 are expressed and not in control fibroblasts, fibroblasts + KLF4 or +p63 alone. C) Heatmap
showing 1154 downregulated genes in fibroblasts + p63+KLF4 compared to control and GO
categories enriched among downregulated genes. D) Heatmap showing co-expression of p63
and KLF4 is required for upregulation of a subset of key epithelial and craniofacial genes. E)
Distance to nearest TSS for all p63 and all KLF4 peaks in fibroblasts +p63+KLF4. F) Partitioning
of p63 and KLF4 peaks into different genomic features showing intergenic and intronic regions
are the most abundant for both G) Distance to closest TSS for p63/KLF4 shared peaks. H)
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Partitioning of 13488 p63/KLF4 shared peaks showing enrichment of intronic and intergenic
regions, consistent with enhancers. I) Alluvial plot depicting changes in chromatin state after
ectopic expression of p63 and KLF4 at p63/KLF4 bound peaks for chromatin transitions with
>200 peaks. J) Boxplot showing H3K27ac is not statistically different (p=0.01) at shared p63
peaks between p63+KLF4 in fibroblasts and p63 in undifferentiated keratinocytes (ChIP-seq
signal at p63 peaks (n=4981) +/- 500bp) (**p-Value<10E-16) K)L) Boxplots showing increased
chromatin accessibility and H3K27ac only at genes upregulated in fibroblasts + p63+KLF4 (*pValue<0.05, **p-Value<10E-16). Very high fold change in H3K27ac at p63/KLF4 peaks close to
upregulated genes.
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Supplemental Figure 2.3: Mutations in p63 disrupt enhancer establishment and lead to
loss of upregulation of key keratinocyte specific genes. A) Heatmap showing mtDBD and
mtSAM have disrupted or loss of upregulation of the top 15 genes upregulated by WTp63+KLF4.
B) Category plot showing 71% (9513/13488) of p63/KLF4 sites are retained when p63 carries
mutations in the SAM domain. C) Heatmap showing mtDBD and mtSAM have disrupted or loss of
upregulation of a subset of epithelial and craniofacial genes. D) UCSC genome browser tracks
showing defects (red box) in establishing open chromatin and inducing gene expression at
LAMB3, a gene involved in craniofacial development.
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Supplemental Figure 2.4: Heatmap of genes regulated by p63+KLF4 that have been
strongly linked to CL/P in murine KD and KO models. A) Heatmap of genes regulated by
p63+KLF4 that have been strongly linked to CL/P in murine KD and KO models.

Supplemental Figure 2.5: p63/KLF4 peaks colocalize strongly with highly associated CL/P
SNPs near IRF6, RHPN2 and GPATCH1. A)B) Overlay of SNPs and UCSC genome browser
tracks highlighting in orange that p63/KLF4 peaks colocalize strongly with highly associated CL/P
SNPs near IRF6, RHPN2 and GPATCH1, in grey binding of both proteins at promoters.
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2.6: Supplemental Table Legends
Supplemental Table 2.1: Genes upregulated in fibroblasts +p63 compared to control fibroblasts,
fold change > 1.5 and FDR < 0.05
Supplemental Table 2.2: Genes upregulated in fibroblasts +p63+KLF4 compared to control
fibroblasts, fold change > 1.5 and FDR < 0.05
Supplemental Table 2.3: Column 1) Genes upregulated in fibroblasts +mtDBD+KLF4 compared
to control fibroblasts, column 2) Genes upregulated in fibroblasts +mtSAM+KLF4 compared to
control fibroblasts, column 3) Genes no longer upregulated in fibroblasts +mtSAM+KLF4
compared to WTp63+KLF4, column 4) Newly upregulated genes in fibroblasts +mtSAM+KLF4
compared to WTp63+KLF4; fold change > 1.5 and FDR < 0.05
Supplemental Table 2.4: A) Representative genes involved in isolated CL/P or CPO in murine
KO/KD models and transcriptional regulation in control fibroblasts, fibroblasts + WTp63+KLF4
and fibroblasts +mtSAM+KLF4 and replicates. B) List of 76 genes upregulated by p63+KLF4
identified by genetic association database. C) List of 40 known risk loci for nsCL/P and genes
within the TAD domains of each loci, in orange, genes upregulated by p63+KLF4. D) List of
p63/KLF4 regulated genes and respective gene based CL/P association p-values for known
causal genes, genes within the 40 risk loci and genes outside of the known risk loci.
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Chapter 3: KMT2D regulates p63 target enhancers to coordinate epithelial
homeostasis

3.1: Introduction
Proper regulation of epigenetic information through the precise control of gene enhancer
1

and transcriptional networks is essential for establishing and maintaining cell fate and identity .
Disruption of these pathways critical for differentiation can lead to a loss of proliferative control,
2

ultimately driving carcinogenesis . In line with this, the gene encoding the chromatin modifier and
master enhancer regulator KMT2D (MLL4) is amongst the most frequently mutated genes in
human cancer

3,4,5,6,7

. There is an exceptionally high prevalence of KMT2D mutations in self-

renewing epithelial tissues ranging from the lung and esophagus to the skin and bladder, with the
highest frequencies seen in keratinocyte cancers (cutaneous squamous cell carcinoma and basal
7,8

cell carcinoma), the two most common forms of cancer world-wide .
Functionally, KMT2D, along with the related protein, KMT2C (MLL3), are the major
histone methyltransferases that deposit histone H3 lysine 4 (H3K4) monomethylation (H3K4me1),
which poises enhancers for activation and transcription factor binding

9,10,11

. Furthermore, in

addition to its catalytic role in H3K4me1 deposition, KMT2D is also required for the binding of the
histone acetyltransferase complex, CBP/p300, which acetylates H3K27 (H3K27ac) at enhancers,
resulting in enhancer activation during cell identity gene induction and changes in cellular
fate

12,13,14

11

. In mice, complete deletion of Kmt2d is embryonic lethal . Tissue-specific deletion

studies have demonstrated that KMT2D is essential for the normal development and function of
11

15

enhancers during adipogenesis and myogenesis , cardiac development , and B-cell lymphocyte
development

16,17

.

Despite the high incidence of KMT2D mutations in the epidermis, and established roles in
enhancer function and developmental programs in other tissues, little is understood about
KMT2D function in normal epithelial homeostasis. Given the poor understanding yet potential
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importance of KMT2D in development and cancer, here we explore the role of KMT2D in selfrenewing epithelia and provide the first description of KMT2D’s role at epithelial enhancers,
including its genome-wide interactions with the transcription factor p63, master regulator of
epithelial transcription, in coordinating key gene expression programs required for both epithelial
cell identity and the maintenance of epithelial progenitors.

3.2: Results
3.2.1: KMT2D depletion leads to reduced proliferation and reduced expression of epithelial
development and adhesion genes
To study KMT2D in the epithelium, we reduced KMT2D levels in primary neonatal human
epidermal keratinocytes (NHEKs) and in spontaneously immortalized human epidermal
keratinocytes (HaCaTs), using short hairpin RNAs directed against KMT2D (shKMT2D)
compared to scrambled control shRNA (shSC). RNA-seq carried out in both the NHEK and the
HaCaT shRNA-treated keratinocytes demonstrated a significant reduction in KMT2D expression
(Fig. 3.1A). This was confirmed by employing three distinct shKMT2D hairpins which displayed a
consistent 2-3 fold reduction in KMT2D expression using RT-qPCR, western blotting, and
immunofluorescence (IF) (Supplemental Figs. S3.1A-C, Fig. 3.1B). In addition, proliferative
growth of shKMT2D keratinocytes was reduced by KMT2D loss compared to shSC keratinocytes
(Fig. 3.1C), consistent with previous reports in other cell types

18,19

. To confirm that the reduced

proliferative capacity did not reflect a simple global stress response, we examined levels of the
senescence-associated tumor suppressor, p16/CDKN2A, and the stress and senescenceassociated transcription factor, phospho-NF-κB p65 (Ser536), and did not observe any
differences between either shSC or shKMT2D keratinocytes (Supplemental Fig. S3.1C).

67

Figure 3.1: KMT2D loss leads to reduced keratinocyte proliferation and a broad loss of
epithelial development and adhesion genes. (A) KMT2D mRNA expression is significantly
reduced in both NHEK (p = 0.0036) and HaCaT (p = 0.0312) keratinocytes treated with shKMT2D
as determined by RNA-seq. (B) shKMT2D keratinocytes display reduced levels of KMT2D, but
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normal-appearing nuclear morphology. (C) shKMT2D keratinocytes display reduced proliferation
in comparison to shSC keratinocytes. (D) Representative genes from shKMTD NHEKs that are
significantly reduced in expression along with corresponding adjusted p-values. (E) Gene
Ontology (GO) analysis of the 134 common genes lost with shKMT2D-treatment between both
NHEK and HaCaT shKMT2D keratinocytes demonstrates that genes involved in key epithelial
signaling pathways (RARG, VDR), epithelial cell growth and morphogenesis, polarity, and
adhesion are enriched in amongst those genes with reduced expression. (E) shKMT2D
keratinocytes display reduced expression of RARγ and VDR by IF (40x).

Given KMT2D’s importance in transcriptional enhancer function, we examined the
transcriptional consequences of KMT2D depletion in keratinocytes. We performed 3 biological
replicates of RNA-seq from NHEKs treated with shKMT2D. Strikingly, we found a broad reduction
in the expression of genes critical for epithelial development and differentiation, as well as
adherence to the epidermal basement membrane (Fig. 3.1D). These encode proteins involved in
epithelial development, migration, and differentiation (CYP27B1, GRHL2, PDFGB, PRKCH,
RARG, SOX7, VDR, WNT10A)
(DLG3, DLG5, WNT7A)

26

20,21,22,23,24,25

, the establishment and maintenance of cell polarity

, cellular adhesion and the extracellular matrix organization (CLDN11,

CNTN1, EMP2, IL4R, LOXL1, LOXL2, SERPINE1)

27,28

, and included disease-associated

markers of interfollicular basal epidermal stem cells essential for the function of the epidermal
basement

membrane

(COL4A2,

ITGA3,

ITGA5,

ITGB2,

ITGB4,

LAMA5,

LAMB2)

29,30

(representative genes in Fig. 3.1D, and full list in Supplementary Table S3.1A). Similarly, we also
performed 3 RNA-seq replicates in the HaCaT keratinocytes treated with shSC and shKMT2D.
Overlap of all significantly reduced genes (adjusted p-value < 0.1) from both sets of keratinocytes
demonstrated a significant overlap in the transcriptional alterations observed with shKMT2D
treatment (134 overlapping genes, p = 3.57e-76) (Supplementary Fig. S3.1D). Gene Ontology
(GO) analysis was carried out on the common 134 genes and showed enrichment of genes
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related to cellular growth, extracellular matrix organization, and adhesion, including key genes
involved in epithelial development, differentiation and morphogenesis. Notably, the vitamin D
signaling pathway, a key cell signaling pathway involved in epithelial differentiation was also
23

among the most enriched pathways (Fig. 3.1E and Supplemental Table S3.2A) . Visualization of
the keratinocytes by IF confirmed the loss of expression of representative genes such as RARG
and VDR (Fig. 3.1F, G). Collectively, these results show that KMT2D reduction drives a broad
loss of key genes typically expressed by epidermal stem and progenitor cells of the basal layer,
as well as genes involved in proper epidermal differentiation, together suggesting a role for
KMT2D in maintaining the hallmark gene expression program and proliferative capacity
characteristic of epithelial progenitors.

3.2.2: KMT2D is enriched genomewide at p63 target enhancers
To gain further insight into the function of KMT2D in the epidermis and the mechanism
underlying keratinocyte gene expression, we mapped KMT2D binding genome-wide using
chromatin immunoprecipitation (ChIP)-seq (full mapping information in Supplementary Table
S3.3A). Consistent with its role in gene regulation at enhancers, a total of 1,887 KMT2D ChIP-seq
binding sites were analyzed by DiffBind

31

and HOMER suite, among which half of KMT2D peaks

(52%) bound to intergenic regions, while introns (and likely intronic enhancers) made up the
majority of the remaining binding sites (40%) (Fig. 3.2A). Analysis of the nearest gene to each
peak showed that 76% of peaks were associated with protein-coding genes, while the majority of
the others occurred near non-coding RNAs (22%) (Fig. 3.2B).
We evaluated transcription factors binding motifs that were enriched at KMT2D binding
regions. HOMER motif analysis of all KMT2D peaks identified p63, considered the master
32

regulator of epithelial development and differentiation , as the most highly enriched transcription
factor motif at KMT2D binding sites (Fig. 3.2C). To examine the overlap of KMT2D peaks with
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p63 binding sites, we intersected the nearest gene to our KMT2D peaks with consensus
previously published p63 binding site-associated genes

33,34

. We verified that KMT2D peaks

indeed overlapped directly with p63 binding sites in shSC keratinocytes using ChIP-seq. Although
our p63 antibody identified fewer total binding sites than observed in previous reports

33,34

, our

data suggested that p63 and KMT2D bound to overlapping sites across the genome, as 49% of
p63 peaks contained a directly overlapping KMT2D peak, while another 13% of p63 peaks were
with 100kb of a KMT2D peak. Overlapping peaks included known p63 target genes such as
MINK1, SERINC2, and TP63 itself (Figs. 3.2E-G).

Figure 3.2: KMT2D co-localizes with p63 genome-wide at p63 target genes. (A) Consistent
with its role in enhancer function, KMT2D binding is enriched in control (shSC) keratinocytes at
intergenic and intronic regions genome-wide. (B) Over 75% of KMT2D binding sites in control
(shSC) keratinocytes are associated with protein-coding genes, with the majority of the remaining
binding sites associated with non-coding RNAs (ncRNAs). (C) HOMER motif analysis of KMT2D
binding sites in shSC keratinocytes reveals a strong enrichment at p63 binding motifs. (D)
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Intersection of consensus established p63 binding sites in keratinocytes with KMT2D binding
sites in shSC keratinocytes demonstrates a significant overlap (p = 1.87e-142). (E) ChIP-seq for
both KMT2D and p63 in shSC keratinocytes demonstrates that KMT2D binds at the same sites
as p63 at known p63 target genes such as MINK1, SERINC2 (F), and TP63 itself (G).

3.2.3: KMT2D and p63 interact on chromatin
We next wanted to test for a potential direct interaction between KMT2D and p63.
Importantly, chromatin co-immunoprecipitation experiments in NHEKs were consistent with the
ChIP-seq data in showing that KMT2D interacts with p63 on chromatin (Supplemental Fig.
S3.2A). In line with data showing that the ∆Np63 isoform of p63 is the predominant form of p63
active in the epidermis, using a ∆Np63 specific antibody we determined that KMT2D interacts
with the α, β and γ isoforms of ∆Np63, and suggesting that this interaction is not mediated by the
C-terminal sterile alpha motif (SAM) or the transactivation (TA) domains absent in the ∆N forms of
p63 (Supplemental Fig. S3.2B). Formaldehyde crosslinking followed by immunoprecipitation and
mass spectrometry (IP-Massspec) further confirmed that p63 and KMT2D interact on chromatin
(Figs. 3.3A,B). Intriguingly, these data also suggest that this interaction may in fact be mediated
by a shared interacting partner of the more than 1000 that we identify here for the first time (Figs.
3.3A, B, Supplemental Fig. S3.3A-C, and Supplemental Table S3.4).

Figure 3.3: KMT2D interacts with p63 on chromatin. (A) Formaldehyde crosslinking followed
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by IP-Mass Spec shows p63 and KMT2D interact on chromatin, as immunoprecipitated KMT2D is
able to pull down p63, and immunoprecipitated p63 is able to pull down KMT2D. We further
observe over 1000 shared interacting partners. (B) IP-Mass Spec identifies new and known (i.e.
RBBP5 and ASH2L) interactors of KMT2D. p63 is identified as an interactor of KMT2D in both
crosslinked NHEKs and uncrosslinked and DNAse treated undifferentiated and differentiated
NHEKs.

3.2.4: KMT2D enrichment at p63 targets maintains expression of many key genes involved
in epithelial homeostasis
To test the effects of KMT2D loss, we also performed KMT2D ChIP-seq on the shKMT2D
keratinocytes. Hierarchal clustering showed that both shSC and the shKMT2D samples clustered
31

with their respective replicate dataset (Fig. 3.4A). According to DiffBind , which employs a
stringent peak-based approach, of the 1,887 total KMT2D peaks, 198 were identified as having at
least a 2-fold loss of KMT2D peak size (Fig. 3.4B heatmap and black line in Fig. 3.4C metaplot).
In addition, in order to capture more of the KMT2D changes in enrichment that we observed in
our primary data with shKMTD-treatment, we also employed a non-peak-based approach by
comparing the tag density (AUC) alterations in ChIP-seq enrichment with shKMT2D treatment.
This approach identified 2,271 regions of at least a 2-fold decrease in KMT2D enrichment in
shKMT2D keratinocytes in comparison to shSC keratinocytes (Supplementary Table S3.3A). In
contrast, just 43 regions across the genome demonstrated a 2-fold or greater increase in KMT2D
enrichment (Supplementary Table S3.3B). Consistent with KMT2D’s interaction with p63 and
binding at the same sites on chromatin, motif analysis of KMT2D reduced enrichment regions in
shKMT2D keratinocytes once again showed that p63 was the most highly enriched transcription
factor motif (Fig. 3.4D). In contrast, regions that gained KMT2D were enriched for transcription
factors associated with epidermal differentiation including CEBPβ and AP1-associated factors,
BATF and Fra1 (Fig. 3.4E)

35,36,37

.
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Figure 3.4: KMT2D depletion leads to a preferential loss of KMT2D at p63-target gene
enhancers. (A) Two replicates of ChIP-seq were performed on shSC and shKMT2D
keratinocytes, with shSC and shKMT2D clustering separately with their respective replicate
dataset. (B) Heatmap of DiffBind-identified regions of at least 2-fold changes in enrichment
demonstrates extensive reductions of KMT2D enrichment in shKMT2D keratinocytes. (C)
Metaplots showing average ChIP signal near differential KMT2D binding sites across both
replicates for shSC and shKMT2D keratinocytes. Black line indicates KMT2D-depleted regions,
while red indicates enrichment, and gray indicates unchanged enrichment. (D) HOMER motif
analysis of significantly lost KMT2D regions identifies p63-binding motifs as the most enriched

74

regions of KMT2D loss. (E) The few regions that gain KMT2D enrichment are enriched for
CEBPβ motifs. (F) Intersection of all KMT2D bound region-associated genes (that lose at least
25% enrichment averaged across both ChIP-seq replicates) and established consensus p63binding site-associated genes demonstrates a highly significant overlap (9.75e-127). (G) GO
analysis of the 362 genes that are known p63-binding sites and identified here with reduced
KMT2D enrichment demonstrates that genes associated with hemidesmosomes, cell and
adherens junctions, focal adhesion, are highly enriched.

p63 has a critical role in regulating dynamic enhancers, including super-enhancers critical
for cell identity and cell fate specification, during epidermal development and differentiation

34,38

.

Hence, we explored overlaps between established keratinocyte p63 binding sites and target
genes

33,34

, and genes near KMT2D bound regions, focusing on genes that lost more than 25%

enrichment with shKMT2D across both replicates. Here, the intersection of p63 binding sites and
KMT2D-depleted genes was highly significant (p = 9.75e-127)(Fig. 3.4F and Supplemental Table
S3.3C). GO analysis of these 362 “KMT2D-depleted/p63-target” genes included pathways similar
to above: hemidesmosome assembly, cell and adherens junctions, and focal adhesion (Fig. 3.4G
and Supplemental Table S3.2B); again including genes involved in epidermal development,
stemness, polarity and adhesion (CNTN1, CTNNBIP1, DLG5, ITGA3, ITGB4, LAMA5, LAMC1,
PRKCH, RARG, SERPINE1, SOX7, VDR, WNT7A, WNT10A), many of which are known to be
p63 regulated

27,33,34,39

. Together, these data demonstrate that in keratinocytes KMT2D is enriched

at p63 targets and maintains the expression of many key genes involved in epithelial
homeostasis, including pathways involved in epidermal commitment and stratification such as the
vitamin D and retinoid pathways, as well as numerous genes involved in regulating cell junctions
and adhesion to the epidermal basement membrane.
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3.2.5: KMT2D can drive the expression of p63-target genes through both catalytic histone
methylation activity as well as catalytically independent mechanisms at enhancers.
KMT2D is a histone methyltransferase, thus we assayed relevant histone modifications at
key genes, using ChIP-seq for key enhancer chromatin modifications, H3K4me1 (catalyzed by
KMT2D), and H3K27ac (KMT2D recruits the acetyltransferase CBP/p300)

12,13,14

. We performed

two replicates for each histone modification, and as expected H3K4me1 and H3K27ac clustered
separately (Supplemental Fig. S3.4A). We identified the top 5% depleted regions (and the
nearest associated gene) in each H3K27ac and H3K4me1 ChIP-seq replicate (Supplemental
Table S3.5). Consistent with both the RNA-seq and KMT2D binding data, the top 5% regions of
loss of both H3K4me1 (which KMT2D catalyzes) and H3K27ac (which KMT2D helps coordinate
through recruitment of p300/CBP), were enriched for GO categories involved in focal adhesion,
adherens junctions, and cell migration and proliferation (Supplemental Table S3.5). Overlap of
the KMT2D-depleted/p63-target genes that lost gene expression by RNA-seq with the genes that
lost enhancer histone modification enrichment identified 82 genes (Fig. 3.5A and Supplemental
Table S3.6A). The most highly significant GO categories enriched within these 82 genes involved
development and differentiation, consistent with both our current understanding of the roles of
both p63 and KMT2D (Fig. 3.5B, Supplemental Table S3.2C) as well as our other results
demonstrating the effects of KMT2D depletion on the expression of key genes involved in the
epidermal basement membrane (COL4A2, ITGA3, ITGB4, LAMA5) and epithelial development
and differentiation such as CTNNBIP1, DLG5, EHD1, EHD2, EMP2, PRKCH, RARG, VDR, and
SERPINE1 (Figs. 3.5C, D and Supplemental Fig. S3.4B-G, and Supplemental Table S3.6A). In
addition, there were 20 KMT2D-depleted/p63-target genes losing expression that did not lose
enhancer histone modifications (at least within the top 5% loss for either H3K4me1 and H3K27ac)
(Supplemental Table S3.6B). These genes were also involved in development and adhesion and
included ITGA3, KRT15, IL1B, and SPARC, and TJAP1 (Supplemental Table S3.6B). These
latter observations are consistent with recent evidence suggesting that KMT2D depletion can lead
to extensive gene expression changes that are independent of its histone methyltransferase
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catalytic activity . Collectively, these results indicate that KMT2D can drive the expression of
p63-target genes broadly involved in multiple aspects of epithelial development and
differentiation, both through catalytic histone methylation activity as well as through other
catalytically independent mechanisms at enhancers.

Figure 3.5: KMT2D depletion provokes a loss of enhancer histone modifications and p63target genes. (A) Intersection of the KMT2D-depleted/p63-target genes that lose gene
expression with those that lose enhancer histone modifications (H3K4me1 or H3K27ac) in
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shKMT2D keratinocytes identifies 82 genes. (B) GO analysis of these 82 KMT2D-depleted/p63target genes that lose enhancer histone modifications shows an enrichment for genes broadly
involved in development and differentiation. ChIP-seq tracks from representative genes that lose
KMT2D enrichment at p63 bound regions, as well as enhancer histone modifications. Examples
include VDR (C) and LAMA5 (D).

3.2.6: KMT2D coordinates with p63 to maintain epidermal progenitor gene expression and
proper epidermal differentiation and stratification.
We then examined the genes that were upregulated upon shKMT2D-treatment of
keratinocytes. GO analysis of the common genes that exhibited a significant increase (p<0.1) in
the shKMT2D keratinocytes identified a striking enrichment of genes involved in keratinocyte
differentiation, with the GO category “cornification” displaying an over 40-fold enrichment (Fig.
3.6A). These genes included markers of early epidermal stratification such as KRT10 as well as
canonical transcription factors involved in epidermal differentiation and stratification (KLF4,
GRHL1, GRHL3, ZNF750) (Fig. 3.6B). Other genes significantly increased in shKMT2D
keratinocytes included genes such as KRT16 and KRT17, which are typically associated with
hyperproliferative conditions such as squamous cell carcinoma and psoriasis (Fig. 3.6B and
Supplemental Fig. S3.5A). The combination of data showing a loss of expression of genes
involved in the basal epidermal stem cell layer and the progenitor state, along with the
upregulation of genes associated with keratinocyte differentiation, together suggest that in
undifferentiated keratinocytes, KMT2D expression actively coordinates with p63 to maintain
epidermal progenitor gene expression and thus prevent terminal differentiation.
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Figure

3.6:

KMT2D

depletion

provokes

premature

and

disorganized

epidermal

stratification. (A) GO analysis of the common genes that significantly (p<0.1) gain expression in
shKMT2D keratinocytes identifies genes involved in epithelial cornification, keratinization,
differentiation, and development as being the most enriched. (B) Representative genes that are
upregulated in shKMT2D keratinocytes includes genes encoding proteins that are characteristic
of stratifying epidermis such as KRT10 and IRF6, as well as numerous members of the small
proline rich (SPR) family of genes. Similarly upregulated are transcription factors such as KLF4,
GRHL1, and GRHL3 associated with keratinocyte differentiation. (C) Three-dimensional (3D)
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human organotypic skin cultures demonstrate that shKMT2D keratinocytes display altered
differentiation dynamics, including random premature cornification, a loss of polarity, and
disorganized stratification in comparison to shSC keratinocytes (Hematoxylin and eosin stain,
10x). (D) IF of 3D human skin cultures demonstrates reduced levels of KMT2D throughout the
epidermis in shKMT2D keratinocytes in comparison to shSC keratinocytes (40x). (E) Filaggrin
and loricrin staining of 3D human skin cultures suggests both increased levels as well as
disorganized epidermal stratification (20x).

To address how these chromatin and gene expression alterations may affect human skin,
41

we utilized three-dimensional human organotypic skin cultures . These cultures allow for the
analysis of epidermal genes and proteins during differentiation in a more human and
41

architecturally relevant context than standard submerged cultures . While shSC-treated
keratinocytes displayed a relatively normal appearing epidermis, shKMT2D-treated keratinocytes
appeared highly disorganized, with cells showing a loss of polarity, irregular morphologies, and
premature cornification (Fig. 3.6D), consistent with many of the observed gene expression
changes. IF of these sections confirmed both decreased levels of KMT2D expression (Fig. 3.6C).
Staining for other markers associated with differentiation such as filaggrin and loricrin
demonstrated disorganized stratification dynamics with premature and elevated expression of
these proteins, as well as notable reduction in the expression of keratin 5, a marker of the
epidermal progenitor cells of the basal epidermis (Figs. 3.6D-F). In order to determine whether a
loss of p63-target gene expression was solely responsible for the premature activation of
differentiation-associated genes, we overexpressed p63 in the shKMT2D keratinocytes. While
significant overexpression of p63 was achieved, it was unable to reverse the gene expression
changes observed in the KMT2D-depleted keratinocytes (Supplemental Fig. S3.5B). These
results were not entirely surprising given KMT2D’s critical role in enhancer, transcription, and
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transcription factor dynamics, and suggest that the effects of KMT2D on epithelial homeostasis
and stratification dynamics are more broad than acting simply through p63.

3.3: Discussion
An abundance of evidence has shown that p63 is critical for limb development and
epidermal specification

42,43,44

, and mutations in TP63 are associated with several developmental
45

disorders that display epithelial abnormalities . Over time, p63 has come to be known as the
master regulatory transcription factor of epithelial tissues, playing key roles at multiple levels of
development and differentiation

46,47

. Excitingly, here we present evidence that KMT2D, a major

enhancer histone methylation enzyme, and one of the most frequently mutated genes in epithelial
cancer, is a critical regulator of p63-dependent gene expression programs and epithelial
homeostasis. Our data indicate that KMT2D interacts with p63 on chromatin and at a broad array
of enhancers involved in epithelial development, adhesion, and differentiation. Further, we also
identify numerous potential new interacting proteins that may play a role in mediating the KMT2Dp63 interaction. In turn, depletion of KMT2D in human keratinocytes leads to extensive alterations
in normal epidermal transcriptional programs, characterized by a broad loss of expression of
genes typically expressed in the self-renewing basal epidermal stem cell compartment such as
basal integrin and laminin genes, as well as key regulators of proper epidermal stratification,
including the retinoid and vitamin D signaling pathways

21,23

. In support of our findings, p63 has

been shown to regulate many of the same genes we observe to be regulated by KMT2D here,
including those involved in adhesion and vitamin D signaling

39,48,49

. In response to the loss of the

expression of these genes, genes involved in keratinocyte proliferation (KRT1, KRT10, KRT6,
KRT16, KRT17) and transcription factors that promote terminal differentiation (KLF4, GRHL1,
GRHL3, ZNF750) are prematurely turned on.

81

As one of the largest organs in the body, the skin serves as a major barrier to the
external environment. Similar to other epithelial surfaces, in order to maintain homeostasis, the
epidermis undergoes regular, highly coordinated self-renewal that involves dramatic alterations in
50

gene transcription and cellular architecture . This self-renewal ability is maintained in the
interfollicular epidermis by stem cells in the basal layer that are typically slow cycling, but with a
high proliferative potential and self-renewing capacity, serving to ultimately supply the more
differentiated suprabasal epidermis

37,51

. Our data indicates that KMT2D plays a critical role in

epithelial homeostasis by maintaining the adhesion and proliferative capacity of the epidermal
basement membrane through its interaction with p63 to regulate critical enhancers for genes
involved in both maintaining the basal epidermis as well as in the proper coordination of epithelial
stratification.
Similar to both p63, while KMT2D may be critical for epithelial stem cell maintenance and
gene expression, we cannot rule out that it may also play key roles later in coordinating later
46

steps in terminal differentiation, as does p63 . Indeed, given its effects on genes also involved in
the promotion of epidermal differentiation, such as the vitamin D and retinoid signaling pathways,
it is likely KMT2D also participates in the coordination of all stages of epidermal commitment and
differentiation. Consistent with this model, IF staining of normal skin sections for KMT2D (from
both our lab as well as publicly available datasets) shows the presence of KMT2D in both basal
epidermal stem cells as well as in the nuclei of cells nearing terminal differentiation
(Supplemental Figs. S3.6A, B). This observation may offer insight into why KMT2D has been
shown to serve both as an oncogene as well as a tumor suppressor in cancer, depending upon
the cellular context

4,16,17,53,54

. Here we observe that KMT2D depletion reduces keratinocyte

proliferation, which is consistent with reports that KMT2D deficiency slows the proliferation of both
breast and colon cancer cell lines

19,55,56

, and correlates with improved outcomes in pancreatic

53

cancer . In contrast, our data suggesting a role for KMT2D in regulating genes involved in
vitamin D and retinoid signaling would suggest a potential tumor suppressive role
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23,57

. Indeed,

deciphering these potential oncogenic versus tumor suppressive functions of KMT2D in epithelial
cancers remains a critical question and important direction for future studies.
3.4: Materials and methods
3.4.1:Keratinocyte cultures
Normal primary human epidermal keratinocytes (NHEKs) were isolated from de-identified
discarded neonatal human foreskin obtained by Core B of the Penn Skin Biology and Diseases
and Resource-based Center. Foreskin was incubated for 12 hours at 4C in 2.4 U/ml Dispase
II. Sterile forceps were used to separate the underlying dermis. The epidermal sheet was
transferred to a 60 mm tissue culture plate and incubated in 0.25% Trypsin for 10 minutes at 37C,
then neutralized with 1 ml fetal bovine serum. Sterile forceps were used to scrape the epidermal
sheet against the dish to dissociate cells. The suspension was passed through a 40 um strainer,
and then centrifuged at 200g for 5 minutes. The cell pellet was re-suspended in 5 ml medium
(see below). HaCaT keratinocytes were obtained from AddexBio. Both were cultured in a 50:50
mix of Keratinocyte-SFM (1x) supplemented with human recombinant Epidermal Growth Factor
1-53 and Bovine Pituitary Extract combined with Medium 154 supplemented with Human
Keratinocyte Growth Supplement and 1% Penicillin-Streptomycin (10,000 U/mL) (all from Thermo
Fisher Scientific). For differentiation experiments, NHEKs were cultured in media containing 1.22
mM calcium chloride for 48 hours and then harvested.
3.4.2: Viral transduction
Lentiviral particles expressing scrambled control (SC) or KMT2D (MLL4)-specific shRNAs
(D4, D5, D9) were produced using the pLKO.1-Puro viral backbone plasmid generously provided
by the Xianxin Hua Lab at the University of Pennsylvania. Three KMT2D shRNAs were
employed: KMT2D shRNA D4:
CCGGCCCACCTGAATCATCACCTTTCTCGAGAAAGGTGATGATTCAGGTG; KMT2D shRNA
D5:

CCGGCCTGAATTGAACAACAGTCTTCTCGAGAAGACTGTTGTTCAATTCA;
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KMT2D

shRNA D9: CCGGCGAATGGAAGAACAACGTGTACTCGAGTACACGTTGTTCTTCCATT. For
2

the viral transductions, keratinocytes were infected with virus at 60% confluency on 10cm plates
for 16 hours in the presence of polybrene. 48 hours following infections, cells underwent selection
with puromycin to obtain completely puromycin-resistant cell populations. For the p63overexpression studies, NHEKs at ~60% confluency were transfected with 10µg of pcDNA3.1
deltaNp63alpha-FLAG (Addgene #26979) and 10µl of Lipofectamine2000 diluted in 1ml of
OptiMEM overnight (~16 hours). Cells were placed in fresh media and RNA was harvested 48
hours following the initial transfection.
3.4.3: Growth curve measurement
2

200,000 cells were seeded on 950 mm surface area (one well of 6-well plate) on day 0.
Cell number was measured every two days with Countess automated cell counter (Life
Technologies) following standard procedures and default parameter settings, after which 200,000
cells were plated back for the next count.
3.4.4: Reverse-transcriptase quantitative PCR (RT-qPCR)
RNA was extracted using RNeasy kit (Qiagen) following the manufacturer’s instructions.
cDNA was obtained by and then was analyzed by standard qPCR methods on a 7900HT FastReal-Time PCR (ABI). Primer sequences are available upon request. RT-qPCR data analysis
was performed by first obtaining the normalized QT values (normalized to 18S ribosomal RNA).
The average and standard deviations of biological replicates were obtained and assessed for
significance using an unpaired t test (graphpad.com). For all experiments, 3 stars indicates
P<0.01, 2 stars indicates P<0.05, 1 star indicates P<0.1, and NS indicates non-significance, or
P>0.1.
3.4.5: RNA-seq
RNA was extracted using RNeasy kit (Qiagen catalog no. 74014) and following the
manufacturer’s instructions. All RNA-seq libraries were prepared using the NEBNext Poly(A)
mRNA Magnetic Isolation Module followed by NEBNext Ultra Directional RNA Library Prep Kit for
Illumina (both from NEB). Library quality was checked by Agilent BioAnalyzer 2100 (Agilent) and
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libraries were quantified using KAPA Library Quantification Kits (KAPA Biosystems). Libraries
were then sequenced using a NextSeq500 platform (75bp, single-end reads) (Illumina). All RNAseq was aligned using RNA STAR under default settings to Homo sapiens UCSC hg19 (RefSeq
& Gencode gene annotations). FPKM generation and differential expression analysis was
performed using DESeq2. NHEK and HaCaT RNA-seq each consisted of three independent
biological replicates.
3.4.6: Immunofluorescence
Cultured keratinocytes were fixed in 4% PFA in PBS for 30 minutes at room temperature.
Cells were washed twice with PBS, and permeabilized with 0.5% Triton X-100 in PBS for 10
minutes. After washing two times, cells were blocked in 10% BSA in PBS for 1 hour at room
temperature. Cells were incubated with primary antibodies in 5% BSA in PBS supplemented with
0.1% Tween 20 (PBST) overnight at 4°C. Antibodies are listed below. Then cells were washed
four times with PBST, each for 10 minutes, followed by incubation with fluorophore-conjugated
secondary antibody in 5% BSA in PBST for 1 hour at room temperature. Cells were then washed
three times in PBST, once with PBS, and incubated with 1 µg/ml of DAPI for 5 minutes. The cells
were then washed twice with PBS, and mounted with ProLong Gold (Invitrogen). For the 3Dorganotypic skin cultures and normal human skin sections, following exposure xylene and
ethanol, sections were treated with target unmasking fluid to deparaffinize the tissues. Sections
were incubated in primary antibody overnight following blocking for two hours in BlockAid
(Thermo Fisher Scientific). Following secondary antibody incubation and washes, the sections
were incubated with 1 µg/ml of DAPI for 5 minutes, then washed twice with PBS, and mounted
with ProLong Gold with DAPI (Invitrogen). The slides were observed and imaged using a Nikon
Eclipse microscope.
3.4.7: Antibodies
Antibodies included Anti-Histone H3 (Abcam ab1791), Anti-Histone H3 (mono methyl K4)
(Abcam ab8895), Anti-Histone H3 (acetyl K27) (Abcam ab4729), anti-KMT2D (HPA035977)
(Sigma-Aldrich), anti-p63-α (D2K8X) (#13109 Cell Signaling), anti-p63 (4A4) (Santa Cruz sc-

85

8431), Anti-∆Np63 (Biolegend #619001), Anti-Cytokeratin 16 antibody (EP1615Y) (Abcam
ab76416), Anti-Vitamin D Receptor antibody - ChIP Grade (Abcam ab3508), RARγ Antibody (G1) (Santa Cruz sc-7387).

3.4.8: Mass spectrometry (MS) analysis and protein identification
FLAG-tagged KMT2D protein was transfected (Life Technologies, #11668019) and
expressed in HEK293T cells and FLAG-tagged ∆Np63α was generated by in vitro translation
(Thermo, #88881). Subsequently, both were separately subjected to immunoprecipitation with
FLAG antibody conjugated protein G Dynabeads (Life Technologies, #10004D). Following
stringent washes, equal amount of lysates of undifferentiated or differentiated NHEKs were lysed
for 1 hour at 4˚C in modified RIPA buffer containing 150 mM NaCl, 1% NP-40, 50 mM Tris-Cl, pH
8.0, and 1% SDS, supplemented with protease inhibitors or lysate of undifferentiated crosslinked
NHEKs

(crosslinked/lysed/sonicated

as

above)

were

added.

After

overnight

co-

immunoprecipitation, samples were thoroughly washed using a buffer containing: 20 mM Tris, pH
8.0, 137 mM NaCl, 1 mM MgCl2, 1 mM CaCl2, 1% NP-40, and protease inhibitors. Beads were
resuspended in 50µl of 50mM Ammonium bicarbonate (NH4HCO3), samples were reduced with
0.5µl of 1M DTT at 55˚C for 30min and then cooled down to room temperature. Samples were
then alkylated using 2.5µl of 500mM iodacetamide for 30 min at room temperature and protected
from light. Following this, 1.5µg of trypsin (Promega REF:V511C) was added to each sample and
allowed to digest overnight. The next day samples were subjected to 80˚C for 10min to stop
trypsin digestion. Tubes were placed on a magnet and peptides were transferred to a new tube.
Beads were washed twice with 50% acetonitrile and transferred to the same tube. Finally
samples were dried on a SpeedVac and desalted by stage tipping. After in-beads digestion,
samples were analyzed using nano Liquid Chromatography coupled online to tandem Mass
Spectrometry (nLC-MS/MS). Peptides were loaded onto a 75um I.D x 17cm in-house packed
column (ReproSil-Pur C18-AQ, 3 µm) using an Easy-nLC-1000 (Thermo Scientific, San Jose, CA).
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Peptides were eluted over 75 minutes gradient, 3-35% solvent B (A- 0.1% Formic Acid, B- 80%
Acetonitrile, 0.1% Formic Acid) with a flow rate of 300 nl/min. The nLC was coupled to an
Orbitrap Fusion (Thermo Scientific, San Jose, CA) operating in data-dependent mode (DDA). The
spray voltage was set at 2.3 kV and the capillary temperature 275°C. Full MS scans were
performed within the range 350-1200 m/z at a resolution of 120,000 (at 200 m/z). Data-dependent
MS/MS was performed in the ion trap using top speed mode set to 3 seconds; signals with
+

charge state 2 and higher with an intensity above 10000 counts were automatically selected for
MS/MS fragmentation performed using high-energy collision dissociation (HCD) with normalized
collision energy of 27. MS raw files were analyzed using MaxQuant software (1.6.0.16)

58

.

Parameters for MS/MS database searching included the following: precursor mass tolerance 4.5
ppm; product mass tolerance 0.5 Da; enzyme trypsin; missed cleavages allowed 2; static
modifications carbamidomethyl (C); variable modifications acetyl (protein N-term) and oxidation
(M); label-free quantification method iBAQ; database Homo sapiens (Uniprot, November 2017).
PSMs and protein false discovery rate was filtered for < 0.01.
3.4.9: Chromatin immunoprecipitation followed by sequencing (ChIP-seq)
59

ChIP-seq was performed as previously described . Briefly, keratinocytes cultured in
2

10cm dishes were fixed in 1% formaldehyde for 5 minutes and fixation was quenched with
addition of glycine to 125mM for an additional 5 minutes. Cells were harvested by scraping from
plates, and washed twice in 1x PBS before storage at -80°C. ChIP extracts that were sonicated 9
times for 5 minutes each round (30 seconds sonication with intermediate incubation of 30
seconds per round) using a Bioruptor (Diagenode). All ChIPs were performed using 500 µg of
extract and 2µg of antibody per sample. 30 µl of Protein G Dynabeads (Invitrogen) were used per
ChIP. ChIP DNA was also used to make sequencing libraries using NEBNext Ultra DNA Library
Prep Kit for Illumina (NEB). Library quality was checked by Agilent BioAnalyzer 2100 (Agilent)
and libraries were quantified using KAPA Library Quantification Kits (KAPA Biosystems). Libraries
were then sequenced using a NextSeq500 platform (75bp, single-end reads) (Illumina). Post
sequencing, all data was demultiplexed from the raw reads using Illumina's BCL2FASTQ from
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BaseSpace. Fastq files were aligned to Homo sapiens UCSC hg19. Tracks were visualized using
the UCSC genome browser as described further below.
3.4.10: ChIP-seq bioinformatics analyses
Raw reads were mapped to the reference human genome assembly GRCh37 (hg19)
60

using Bowtie2 local alignment . The alignment result was further processed by SAMtools to
remove low quality alignments (a minimum mapping quality of 10), duplicate reads, reads
mapped to the mitochondria, unplaced (chrUn) and random (chr_random) contigs, and reads
mapped to the ENCODE blacklisted genomic regions. MACS2 was used to identify ChIP-Seq
enriched regions (or peaks)(Zhang et al. 2008), requiring peak calling FDR lower than 0.01.
Distribution of resulting peaks in different genomic regions and motif analysis were conducted
using HOMER suite (“annotatePeaks -size given” and “findMotifsGenome”)

61

. Gene target for

each peak was identified as gene with nearest TSS to the peak. Genome-wide tag density was
computed using BEDTools and UCSC command line utilities to generate tracks for visualization.
Each individual track was normalized to 1 million reads. For each ChIP sample, the
corresponding H3 (for H3K27ac and H3K4me1) or input control (for KMT2D and p63) was
subtracted from track using deepTools. Differential binding sites in shSC and shKMT2D
conditions were identified by the DiffBind Bioconductor package (default parameters). Heatmaps
were also generated by DiffBind. For KMT2D differential binding, we retrieved all sites with 2-fold
differences for downstream analysis. Metaplot showing average ChIP signal near differential
binding sites were generated using deepTools. Further, to include more differential binding sites
that were not identified due to the stringency of DiffBind, a statistical test based differential
analysis was performed. Tag density (AUC) was computed from each normalized, inputsubtracted KMT2D sample using bwtool. For each merged KMT2D peak region, we used
Student’s T-test to examine whether its tag density is significantly different between shSC and
scKMT2D samples. To identify the top 5% regions of histone modification loss, sequence tags for
two replicates of H3K27ac and H3K4me1 ChIP-seq were aligned to the NCBI v37 assembly of
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the human genome (hg19) using bowtie v1.1.1 (parameters -m 1 --best). Peaks were called for
the two replicates using MACS2 callpeak, with matching whole histone subunit H3 ChIP-seq as a
sonication efficiency control (parameters -s 75 -q 0.01). The peak sets for both histone PTMs
were further filtered to use a 0.1% FDR. Peaks were then assessed for losses in the shKMT2D
keratinocytes, and those peaks with a quantitative loss in the 95th percentile were associated to
their nearest gene by distance to the TSS.

3.4.11: Statistics
For Venn diagrams, hypergeometric testing was performed. For RT-qPCR and the
growth curve measurements, the standard error of the mean of three replicates is presented.
Additional statistical methods listed in the “bioinformatics analyses” section above.
3.4.12: Chromatin co-immunoprecipitation and western blot
NHEKs were crosslinked in 1% formaldehyde (FisherScientific) in PBS for 5 minutes at
room temperature. Glycine was used to quench the reaction followed by pelleting, collecting and
lysing the cells as previously described

59

. Lysed cells were sonicated with a Covaris sonicator

(S220). The supernatant was then diluted in the final sonication buffer, split equally, and
subjected to immunoprecipitation at 4˚C overnight with the corresponding antibodies: anti-KMT2D
(HPA035977) (Sigma-Aldrich) and rabbit anti-IgG (Abcam ab46540). 10% of the supernatant was
utilized for an Input control. The next day beads were washed thoroughly with RIPA buffer
consisting of 50mM HEPES-KOH (pH 7.5), 500mM LiCl, 1mM EDTA, 1% NP-40 and 0.7% NaDeoxycholate. Proteins were eluted from the beads in 50mM Tris-HCL (pH 8.0), 10mM EDTA and
1% SDS. Samples were then loaded and separated in polyacrylamide gels followed by transfer to
a nitrocellulose membrane. Membranes were incubated in anti-p63-α antibody (Cell Signaling
D2K8X) and imaged on a GE Amersham Imager 600.

89

3.4.13: Three-dimensional (3D) organotypic human skin cultures
The

3D

organotypic

human

skin

cultures

were

performed

as

previously

described(Simpson et al. 2010). Briefly, J2 3T3 fibroblasts were grown in DMEM+10% FBS. Cells
were released from culture plates using 0.25% trypsin for 5 min at 37C, then re-suspended in
DMEM+10% FBS and counted using a hemacytometer to determine the volume needed to obtain
0.75-1 million fibroblasts per organotypic culture. The required volume was centrifuged in a 50 ml
sterile conical tube at 200g for 5 minutes and the supernatant was removed. The fibroblast cell
pellet was re-suspended in 1/10 the final required volume (2 ml per culture) of 10x Collagen Resuspension Buffer (1.1 g NaHCO3 plus 2.39 g HEPES in 50 ml 0.05 N NaOH) and held on ice.
1/10th the final volume of 10x DMEM (Sigma) was then added and the cells were mixed by
vigorous pipetting. Purified high-concentration rat tail collagen I (Corning) was added and diluted
with sterile dH2O to a final concentration of 4 mg/ml of the final volume. 0.05 N NaOH was added
to a pH of approximately 7. The collagen-fibroblast slurry was mixed by inverting, then 2 ml was
pipetted into the upper chamber of a 6-well transwell insert (Corning) placed within a deep-well 6well tissue culture plate (Corning). The fibroblast-collagen matrices were allowed to polymerize at
37C for 60 min. Then, the matrices were submerged in DMEM+10% FBS and placed at 37C
overnight. The next day, NHEKs were trypsinized, re-suspended in DMEM+10% FBS and
counted to collect 1 million cells per culture, centrifuged at 200 g for 5 min, and the supernatant
was discarded. The NHEK pellet was re-suspended in E-medium supplemented with 5 ng/ml
EGF (Sigma) to a volume of 2 ml per culture. The DMEM was removed from both the upper and
lower chambers of the transwell plates containing the collagen-fibroblast matrices. 2 ml of NHEKs
(1 million cells) were seeded atop each matrix in the upper transwell chamber and 14 ml of Emedium with 5 ng/ml EGF was added to the bottom chamber. The cultures were placed at 37C
overnight. The next day, the medium was aspirated from both the top and bottom chambers of
the transwell. To place the NHEK monolayers at an air-liquid interface and induce stratification,
10 ml E-medium (without EGF supplementation) was added only to the bottom chamber of the
transwell and the cultures were grown at 37C for up to 12 days, feeding 10 ml E-medium every
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other day. To generate protein lysates, the transwell apparatus was removed from the plate and
the organotypic culture was separated from the underlying matrix using sterile forceps. The
culture was transferred into urea sample buffer (8 M urea, 1% SDS, 10% glycerol, 60 mM Tris,
5% beta-mercaptoethanol, pH 6.8) and dissolved by vigorous pipetting using a 25 gauge needle
and a 1 ml syringe. Organotypic cultures were prepared for routine histology by submerging the
culture in 10% neutral buffered formalin for 24-48 hrs.

3.4.14: Data availability
The relevant data sets generated during this study have beenuploaded to NCBI Gene
Expression Omnibus and are availableunder accession numbers GSE110475, GSE110453,
GSE110467, GSM2991421–GSM2991435, and GSM2991609–GSM2991620.
3.4.15: Gene Ontology analyses
All

Gene

Ontology

(GO)

analyses

were

http://geneontology.org/page/go-enrichment-analysis.
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performed

using

PANTHER

at

3.5: Supplemental Figures
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Supplemental Figure S3.1: (A) RT-qPCR confirms a significant loss of KMT2D mRNA
expression with shKMT2D treatment using 3 unique shRNAs in comparison to shSC
keratinocytes. (B) Western blotting demonstrates reduced levels of KMT2D in shKMT2D
keratinocytes. (C) Western blotting also demonstrates no differences in the levels of the tumor
suppressor p16/CDKN2A nor the senescence-associated transcription factor phospho-NF-κB p65
(Ser536). (D) Intersection of the significant (p<0.1) genes with reduced expression in both
shKMT2D NHEK and HaCaT keratinocytes in comparison to shSC keratinocytes demonstrates a
significant overlap of 134 genes (p = 3.57e-76).
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Supplemental Figure S3.2: (A) Formaldehyde crosslinking followed by co-immunoprecipitation
(Co-IP) experiments show that p63 and KMT2D interact on chromatin, as immunoprecipitated
KMT2D is able to pull down p63, while control IgG is not. (B) Using a ∆Np63 specific antibody we
determined that KMT2D interacts with the α, β and γ isoforms of ∆Np63, suggesting the
interaction is not mediated by the C-terminal sterile alpha motif (SAM) domain or the
transactivation (TA) domain absent in the ∆N forms.
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Supplemental Figure S3.3: (A) IP-Mass Spec identifies interactors of p63, e.g. STAT1. KMT2D
is identified as an interactor of p63 in both crosslinked NHEKs and uncrosslinked and DNAse
treated differentiated NHEKs. (B) IP-Massspec of p63 and KMT2D in undifferentiated,
uncrosslinked and DNAse treated NHEKs reveals 256 shared interacting genes, including p63.
(C) IP-Massspec of p63 and KMT2D in differentiated, uncrosslinked and DNAse treated NHEKs
reveals 254 shared interacting genes, including p63.
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Supplemental Figure S3.4: (A) Hierarchal clustering of two replicates of both H3K4me1 and
H3K27ac demonstrates separate clustering of the two unique histone modifications. ChIP-seq
tracks from representative genes that lose KMT2D enrichment at p63 bound regions, as well as
enhancer histone modifications. Examples include EHD2 (B), CTNNBIP1 (C), EMP2 (D),
SERPINE1 (E), and RARG (F).
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Supplemental Figure S3.5: shKMT2D keratinocytes display increased levels of Krt16 staining by
IF in comparison to shSC keratinocytes (40x).
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Supplemental Figure S3.6: (A) IF staining of normal human epidermis with KMT2D antibodies
demonstrates that KMT2D (red) is present both in the basal epidermis (white arrows) that is also
keratin 14 positive, but also in the outer more differentiated layers (yellow arrows), suggesting
that it may play a role at all levels of epithelial stratification and differentiation. (B) Publicly
available immunohistochemistry (IHC) data (antibody HPA035977) from the Human Protein Atlas
displays similar findings of KMT2D’s presence at all levels of the epidermis, including the basal
epidermal layer. (C) Overexpression of p63 in shKMT2D keratinocytes does not rescue the
premature activation of differentiation-associated genes such as KRT1 and KRT10.
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Chapter 4: Conclusions and Future Directions

4.1: Summary and main findings

A key role of transcription factor p63 in mediating epidermal commitment, development,
and differentiation has been extensively demonstrated through mouse models and causative
point mutations in human disease. In mice, knockout of p63 leads to developmental and
morphological defects in the squamous epithelia and epidermis, causing abnormal craniofacial
1,2

development, truncated limbs, and loss of salivary glands, hair follicles, and teeth . In humans,
germline missense mutations in p63 cause ectodermal dysplastic syndromes, which are
3

characterized by orofacial clefting and limb malformations . To date, how p63 engages and
modifies chromatin to promote normal development during these early stages is still being
elucidated.
Here we report a trans-differentiation model as a novel approach to determine the role of
p63 in craniofacial development. We show that p63 can establish epithelial enhancers to regulate
downstream genes and that this process is disrupted when p63 carries mutations derived from
human disease. In particular, our results show a novel mechanism underlying pathogenic p63
mutations, in which failure to open and establish enhancers leads to transcriptional dysregulation.
We integrate our epigenomic data with GWAS datasets derived from nsCL/P patients to identify
novel CL/P candidate genes regulated by p63. We also uncover strong enrichment of nsCL/Passociated SNPs at enhancers established by p63, providing mechanistic insight into how these
SNPs lead to human pathogenesis.

Further, in a follow up study, we identify histone

methyltransferase KMT2D as a key partner of p63 at epithelial enhancers. Our data demonstrates
for the first time a critical role for KMT2D in epithelial homeostasis by maintaining the adhesion
and proliferative capacity of the epidermal basement membrane through its interaction with p63 to
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regulate critical enhancers for genes involved in both maintaining the basal epidermis as well as
in the proper coordination of epithelial stratification.
4

In our first study using an inducible trans-differentiation model converting fibroblasts into
keratinocyte-like cells we demonstrated the following main findings:
1. p63 establishes enhancers to upregulate epithelial and inflammation genes: while
previous studies had focused on the role of p63’s engagement with chromatin during
keratinocyte differentiation

5–7

, de novo engagement of p63 with chromatin had not been

extensively addressed due in part to a lack of tractable human models.

2. Co-binding of p63 and KLF4 leads to robust establishment of enhancers that correspond
remarkably well to bone fide enhancers in basal and differentiating keratinocytes: based
on published reports

8

we expanded our in vitro system to better recapitulate the

epigenetic conditions of early development.

3. Binding of p63 to chromatin is a pre-requisite for enhancer establishment: using a patient
derived p63 mutation in the DBD we show complete loss of p63 binding to chromatin and
loss of enhancer establishment.

4. Binding of p63 to chromatin is required but not sufficient for enhancer establishment: an
AEC patient derived substitution mutation in the SAM domain of p63 leads to a protein
that retains binding to chromatin but shows defects in enhancer establishment. The main
defect is in opening chromatin, pointing towards a potentially novel function of the p63
SAM domain in recruiting chromatin remodelers for enhancer establishment. Further, our
9

results contrast a recent report suggesting the main disease mechanism in AEC is
aggregation of mutant p63, and posits a novel molecular link to explain disease
phenotypes found in these patients.
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5. We identified potential candidate causative genes for cleft lip/palate regulated by p63 at
and outside of known risk loci: by integrating epigenomic data-sets from our transdifferentiation model with GWAS datasets we were able to gain novel insights into
molecular mechanisms underlying nsCL/P. In particular, we were able to prioritize
candidate genes within half of the known risk loci and also identify over 100 new
candidate genes and risk loci for nsCL/P. Importantly, our analysis also has the potential
to identify the enhancers that regulate them.

6. Enhancers established by p63+KLF4 are enriched for SNPs associated with nsCL/P:
using 2 different co-localization analyses we identify enrichment of SNPs associated with
nsCL/P only at newly established enhancers. This thus provides a novel molecular
mechanism for how these SNPs may contribute to disease at a molecular level.

Taken together, our findings in our first study address how p63 binds and remodels chromatin
with its first encounter, identifies and prioritizes nsCL/P candidate genes and the enhancers that
regulate them, and provides new explanations for how p63 mutations and SNPs associated with
nsCL/P underlie disease.
7

In our second study we wanted to ask which proteins interact with p63 on chromatin to
establish enhancer structure. We identified methyltransferase KMT2D interacting with p63 at a
broad array of enhancers involved in epithelial development, adhesion, and differentiation. The
main findings in this study were:
1. KMT2D plays a key role in maintaining the hallmark gene expression program and
proliferative capacity of epithelial progenitors: KMT2D, one of the most frequently
mutated genes in human cancer, has been extensively characterized. However, its
role in epithelial cells and homeostais had not been previously explored. We show
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depletion of KMT2D leads to reduced proliferation and reduced expression of
epithelial development and adhesion genes, including DLG2, RARG, ITGB4 and
LAMB2.

2. KMT2D is enriched genomewide at p63 target enhancers: ChIP-seq analysis
demonstrated that KMT2D and p63 are enriched at overlapping sites across the
genome, with as high as 49% of p63 peaks in keratinocytes containing a directly
overlapping KMT2D peak. Many of these included known p63 target enhancers, such
as MINK1, SERINC2, IRF6 and TP63 itself.

3. KMT2D and p63 interact on chromatin: formaldehyde crosslinking followed by
immuno-precipitation and mass spectrometry show p63 and KMT2D interact on
chromatin. We also find over 1000 shared binding partners which could mediate this
interaction.

4. KMT2D is enriched at p63 targets and maintains the expression of key genes
involved in epithelial homeostasis: Knock down(KD) of KMT2D shows reduction of
KMT2D at p63 target enhancers and reduction of gene expression of corresponding
genes. Pathways affected include epidermal commitment and stratification, as well as
cell junction and adhesion.

5. KMT2D can drive expression of p63-target genes through both catalytic histone
methylation activity, as well as catalytically independent mechanisms at enhancers:
Profiling of H3K4me1 (catalyzed by KMT2D) and H3K27ac (KMT2D recruits the
acetyltransferase CBP/p300

10–12

) shows KD of KMT2D correlates with loss of

H3K4me1 and H3K27ac at p63 regulated enhancers of 82 genes involved in
development and differentiation. In another 20 loci we observe loss of gene
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expression with no changes in H3K4me1 and H3K27ac, consistent with recent
evidence demonstrating histone methyltransferase independent functions of KMT2D
13

in regulating gene expression .
6. KMT2D coordinates with p63 to maintain epidermal progenitor gene expression and
proper epidermal differentiation and stratification: Investigation of genes upregulated
upon KD of KMT2D showed a striking enrichment of genes involved in keratinocyte
differentiation, including canonical genes, such as KLF4, GRHL1, GRHL3 and
ZNF750. Using a three-dimensional human organotypic skin culture we observed
keratinocytes treated with shKMT2D showed disrupted stratification dynamics, as
well as premature cornification. Together with the above findings these results
demonstrated a key role of KMT2D in maintaining epidermal progenitor gene
expression and preventing terminal differentiation.
In conclusion, we provide the first description of KMT2D’s role at epithelial enhancers,
including its genome-wide interactions with the transcription factor p63 to coordinate key gene
expression programs required for both epithelial cell identity and the maintenance of epithelial
progenitors.
For an extended discussion on both studies, please refer to the discussion section of
chapter 2 (pages 45-49) and chapter 3 (pages 80-81).

4.2: Future directions

The studies described in chapter 2 and 3 greatly increased our knowledge about p63’s
role in epithelial enhancer establishment and revealed a potential disease mechanism in orofacial
clefting, connecting SNPs and enhancer regulation. Further, they provided insight into possible
binding partners of p63 at enhancers, including histone methyltranferase KMT2D; and described

108

a previously unknown role of KMT2D in maintaining epithelial homeostasis. However, many
questions remain. In the following sections I will describe open questions and possible follow up
experiments.

4.2.1: Dissecting how specific SNPs may cause CL/P
In chapter 2 we found SNPs highly associated to CL/P are enriched at newly established
enhancers by p63 and KLF4. We further discussed in detail two loci that are prominently linked to
CL/P but where a molecular mechanism to explain disease has yet to be found: 8q24 locus and
MAFB locus

14–17

. Our colocalization analyses identified in both cases newly established

enhancers by p63 and KLF4 colocalize with SNPS highly associated to CL/P, however how these
SNPs cause disease remains to be shown. In particular, in these 2 cases and in many other
examples we find several enhancers (exhibiting open chromatin and de novo H3K27ac)
established by p63 and KLF4 and it remains unclear if all are necessary for downstream
regulation of gene expression. Further, in the case of the 8q24 locus and other known risk loci,
the exact genes affected by the SNPs have not been determined. To start to answer these
questions it would be interesting to test some of these enhancers using luciferase reporter
systems to see if they are active in human keratinocytes and our trans-differentiation model, as
well as during epidermal development and development of the lip and palate in murine models.
SNPs could easily be integrated into these enhancer reporter assays to test their effect in gene
expression. A more thorough, albeit technically challenging alternative is to use CRISPR systems
to introduce specific SNPs either in our trans differentiation model or an epidermal differentiation
model derived from pluripotent stem cells, to test how they affect downstream gene expression
and differentiation.
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A more high-throughput possibility to identify how newly established enhancers regulate
downstream gene expression is using chromatin capture assays to study whether these newly
established enhancers are looping to promoters. Looping to promoters could then be correlated
with differential gene expression to filter key enhancers and corresponding SNPs to test.
Another observation from our studies is that many nsCL/P highly associated SNPs
cluster around established enhancers but do not seem to be found within regulatory elements
(based on chromatin signature). Whether these SNPs are simply in linkage disequilibrium with
disease causative SNPs or actively contribute to disease through independent mechanisms
remains to be elucidated. The experiments proposed above would start to shed light into these
processes and greatly expand our knowledge around cleft lip/palate pathogenesis.

4.2.2: Understanding the role of lncRNAs in epidermal specification and differentiation
Another exciting result from our trans-differentiation experiments is that many lncRNAs
become de novo expressed after establishment of enhancers by p63 and KLF4. In particular, in
the 8q24 risk locus, which shows the strongest effect size across populations of Asian and
European origin

18

we observe de novo expression of lncRNA LINC00977. How and whether this

and other lncRNAs regulate epidermal specification and differentiation, as well as more complex
processes such as lip and palate development is not understood. A recent study harnessed the
versatility of gene editing tools to probe how lncRNAs could confer resistance to melanoma
19

treatments . By using an enzymatically inactive Cas9 (dCas9) version coupled to an activating
VP64 protein complex targeted to over 10000 lncRNA promoter regions they were able to screen
which ones conferred a resistance phenotype, suggesting a role for specific lncRNAs in this
process. To begin to understand the role of lncRNAs in epidermal specification and
differentiation, I propose a similar screen. We could target a large amount of lncRNAs in human
keratinocytes with either activation (dCas9-VP64) or repression (dCas9-KRAB) while in parallel
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inducing keratinocyte differentiation using calcium supplemented media. After three days of
differentiation, keratinocytes can be sorted using basal vs differentiation surface markers.
Comparison of sgRNA counts can then point us towards lncRNAs crucial for keratinocyte
differentiation. We could then confirm their function using three-dimensional skin organotyoic
cultures as described in chapter 3 and then test their role in development using murine models.

4.2.3: Identifying new SNPs associated to CL/P and CPO
A remarkable finding from the GWAS data on CL/P is that the 40 identified risk loci
explain about 25% of the cases of non-syndromic cleft lip/palate

20,21

. This is particularly surprising

given the small sample sizes profiled (between 100-1000 patients per cohort). Most of the data
has been collected from patients of Asian and European descent. In order to better understand
genetic effects and how non-coding regions can cause orofacial clefting, it is imperative to
increase the number of patients sequenced, as well as expanding to diverse non-European
populations. Further, while GWAS have provided important insight into CL/P, much more remains
unknow about cleft palate only (CPO) pathogenesis. To date, only a single risk loci has been
22

confidently identified to explain CPO . A major challenge here is the lower incidence of cases, as
well as lack of large samples of data collected in these populations.

4.2.4: Understanding discordant phenotypes in identical twins with p63 mutations
A key observation in patients with p63 substitution mutations is that all patients found so
far are heterozygous for the mutation and that even patients with the same mutation show very
different phenotypes. Given the severe phenotype observed in mice with homozygous deletion of
Trp63 (encoding for p63 in mice)

1,2

it is likely that complete loss of function of p63 in humans is
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embryonically lethal. A recent study

23

reported the first case of monozygotic twins carrying a p63

mutation in the DBD. Interestingly, the twins exhibited discordant phenotypes, with one twin
showing limb malformations and normal craniofacial development and the other showing normal
23

limb development but CL/P . Together with our studies and the fact that p63 acts as a tetramer,
this suggests there is an important dose and spatiotemporal component to p63’s epithelial
enhancer establishment during development. Previous studies looking at heterogenous
composition of tetramers in p53 found that tetramers composed of at least three mutant p53
24

proteins showed impairment of transcriptional activity . It is possible that a similar effect is seen
in patients carrying a substitution mutation in one of their p63 alleles. To test this hypothesis, it
would be interesting to overexpress wildtype p63 in a cell line that does not endogenously
express it. In parallel, mutant versions of p63 could be introduced under a doxycycline inducible
promoter and effects on gene expression could be monitored. It would also be interesting to
obtain keratinocytes from the monozygotic twins mentioned above and profile active enhancers to
see if there are specific differences in enhancer structures. Given the stochastic nature of
tetramer formation, it may be possible that defects on enhancer establishment and gene
regulation may be lost within a population of cells. A better system would be to utilize a murine
model in which a substitution mutation is introduced in a single allele of p63 followed by
monitoring diverse phenotypes, more effectively recapitulating the spatiotemporal and dose
dependent nature of p63’s enhancer establishment in development.

4.2.5: Translation to treatment to prevent orofacial clefting
An important question is how a better understanding of p63’s role in orofacial clefting can
be translated into therapy, especially since CL/P is one of the most common congenital
20

malformations reported, second only to heart congenital malformations . Firstly, in the case of
patients carrying a substitution mutation in p63, patients could possibly benefit from silencing of
the mutant allele during development. This idea is bolstered by the observation that mice with
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homozygous deletion of p63 show severe phenotypes that are lethal shortly after birth, while
heterozygous mice with only 1 allele of p63 deleted show no difference compared to mice with
25

two copies of WT p63 . How this would be achieved in human embryo development is presently
unclear, a therapy involving allele specific siRNA or a small molecule inhibitor that only
recognized mutant versions of p63 are a possibility but must be thoroughly tested for safety and
efficiency.
Downstream pathways affected by p63 enhancer establishment may provide less
disruptive treatment possibilities to prevent orofacial clefting. For example, we observe p63
establishes enhancers upstream of folic acid receptors FOLR1 and FOLR3 and that
establishment of enhancers is followed by de novo expression of the respective genes in our
trans-differentiation model. In mice it has been observed that KO of folbp1 (encoding for the
26

homolog of FOLR1 in mice) leads to orofacial clefting . This phenotype can be mitigated by
supplementation of folic acid during embryo development in these mice. Similarly, it may be
possible that defects in enhancer establishment in humans due to SNPs at enhancers of folic acid
receptors lead to poor upregulation of these receptors and that risk of orofacial clefting might be
mitigated through supplementation of folic acid in families that carry these SNPs.

4.2.6: Molecular mechanism behind birth defects observed with thalidomide treatment
Thalidomide, a drug used in the 1950s to treat morning sickness in pregnant women lead
27

to over 10.000 infants with birth defects in Europe . For almost 60 years, the molecular
mechanisms behind the resulting birth malformations were poorly understood. A recent study
27

showed degradation of SALL4 as an important pathway in thalidomide induced birth defects .
Remarkably, the phenotypes observed in newborns, included limb and craniofacial malformations
(e.g. CL/P) and closely mirrored the developmental phenotypes observed in patients carrying
mutations in p63. Because of the high similarities in the phenotypes it is possible that thalidomide
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interferes in epithelial lineage specification and enhancer establishment via p63. To test whether
this is the case, it would be interesting to supplement cells in the fibroblast to keratinocyte-like
trans-differentiation model with thalidomide at different doses and see if enhancer establishment
is dysregulated. Presently, thalidomide continues to be used to treat a diverse array of diseases,
from erythema nodosum leprosum to multiple myeloma. Treatment is correlated with significant
28

adverse effects in the central nervous system, cardiovascular system and the dermis .
Understanding whether thalidomide interferes with enhancer establishment could provide
important understanding of adverse effects associated with this drug.
4.2.7: p63’s role in cancer and other disorders
While p63 initially garnered huge interest due to the high degree of sequence identity
25

compared to p53, it was not shown to play a similar role in tumor suppression . However, it has
been observed that p63 is downregulated in some cancers undergoing epithelial to mesenchymal
transition

29,30

, suggesting a key role of p63 in protecting and maintaining epithelial identity.

Intriguingly, in a subset of squamous carcinomas, p63 has been shown to be overexpressed, and
31

overexpression has been connected to poor outcomes . Based on the results of our studies, it
would be interesting to study how enhancer landscape changes with loss or overexpression of
p63 in cancer. Particularly, in cancers where p63 is overexpressed, specific enhancers might be
aberrantly established to modulate a gene expression program conducive to tumor growth and
maintenance. Some evidence for this was recently reported in a subtype of pancreatic ductal
31

adenocarcinoma ; however, evidence in other cancer subtypes remains to be elucidated.
Another interesting phenotype observed in p63 KO mice and human patients carrying
substitution mutations of p63 is T-cell lymphopenia

32,33

. It has been demonstrated that p63 plays
32

an important role in the development of the thymic epithelium . Importantly, in our first study we
observed upregulation of genes involved in immune function when p63 was overexpressed by
itself in dermal fibroblasts. Thus, our system might provide novel insight into T-cell lymphopenia
and other diseases involved in T-cell development and maturation.
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4.2.8: Mass spectrometry to dissect what parts of p63 recruit chromatin modifiers and
other proteins to establish enhancers
Our experiments introducing substitution mutations in p63 revealed that the SAM domain
of p63 is crucial for promoting open chromatin during enhancer establishment in epithelial lineage
specification. Nevertheless, it remains unclear which proteins can engage and interact with the
SAM domain of p63 to achieve this and it is also unknown how substitution mutations disrupt this
process. To identify novel interacting partners, it would be interesting to clone and recombinantly
purify a WT and a mutated version of the p63 SAM domain, followed by binding to a column and
flow through of keratinocyte cell lysate. To the best of our knowledge, such a study has not been
conducted yet. Interacting partners could then be isolated and probed using conventional bottomup mass spectrometry methods, as shown in chapter 3. These could then be validated in our
trans-differentiation model using shRNA knock downs to study their effects on chromatin
remodeling and enhancer establishment.

4.2.9: Integration of GWAS data and epigenomics in other diseases
Around 85% of human DNA under evolutionary constraint corresponds to non-coding
protein-sequences

34,35

a large fraction of which correspond to cis-regulatory elements. To date,

many examples have been reported in which genetic variation at these sequences can cause
disease

36–39

. At the same time, a plethora of GWAS studies have been carried out for all kinds of

diseases, from rheumatoid arthritis to coronary heart disease and bipolar disorder. A main
takeaway from these studies is that the vast majority of disease associated SNPs are not found
within exons but rather at intronic and intergenic regions. While more recent studies have begun
to combine gene expression data and expression quantitative trait loci (eQTLs) with GWAS
40

data , they have garnered limited success. Particularly in the case of development, integration of
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trans-differentiation and in vitro differentiation strategies similar to the one we show in chapter 2
could provide better insight into how specific SNPs may alter cis-regulatory elements to modulate
gene expression.

4.2.10: KMT2D in cancer
The gene encoding the histone methyltransferase KMT2D is amongst the most frequently
mutated genes in human cancer

41–45

. Previous studies have reported conflicting roles for KMT2D

either as an oncogene or as a tumor suppressor in cancer, dependent on cellular context

42,46,47

.

Our results in chapter 3 demonstrated that KMT2D depletion reduces keratinocyte proliferation,
which is consistent with reports that KMT2D deficiency slows the proliferation of both breast and
colon cancer cell lines

48,49

50

, and correlates with improved outcomes in pancreatic cancer . In

contrast, our data suggesting a role for KMT2D in regulating genes involved in vitamin D and
retinoid signaling would suggest a potential tumor suppressive role

51,52

. Indeed, deciphering these

potential oncogenic versus tumor suppressive functions of KMT2D in epithelial cancers remains a
critical question and important direction for future studies. Interestingly in pancreatic ductal
adenocarcinoma reduced expression of KMT2D has been reported to correlate with better
50

outcome , while overexpression of p63 has been demonstrated to lead to enhancer rewiring and
31

poor outcome , pointing towards a role of KMT2D together with p63 in driving carcinogenesis in
this type of cancer. More experiments must be conducted to understand how these proteins
function together in the context of pancreatic cancer.
An additional intriguing observation from our mass spectrometry studies in chapter 3 is
that KMT2D and wild type p53 can interact directly. A previous study from our lab showed that
mutant p53 could interact with KMT2A, an H3K4 methyltransferase in the same family of proteins
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53

as KMT2D, to drive cancer growth . Given the key role of p53 in tumor suppression, it would be
interesting to further characterize the interaction between these two proteins in the context of
normal tumor suppression and in cancer.
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